Skip to main content
Psychedex
Sources
39
12 strong · 15 moderate · 12 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
115
96verified9partial8inconclusive2not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 8, 2026 · pipeline-v5
Values approved
98/98 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold0.2 mg0.2 mgmedium
Low0.5–1 mg0.5–1 mgmedium
Common1–2 mg1–2 mgmedium
Strong2–5 mg2–5 mgmedium
Heavy5+ mg5+ mgmedium
Editorial

Existing DB values verified against clinical trial doses: Casacchia 1990 tested 0.25 mg and 0.5 mg BID (0.5–1 mg/day total) as therapeutic range, placing these firmly in the light-to-common range. Bertolino 1989 used 0.5 mg BID. Therapeutic ceiling is approximately 1 mg BID (2 mg/day). Recreational dose tiers above 2 mg rely on community consensus (PsychonautWiki, Erowid). Threshold at 0.2 mg is below the minimum clinical trial dose.

Reasoning

Existing DB values verified against clinical trial doses: Casacchia 1990 tested 0.25 mg and 0.5 mg BID (0.5–1 mg/day total) as therapeutic range, placing these firmly in the light-to-common range. Bertolino 1989 used 0.5 mg BID. Therapeutic ceiling is approximately 1 mg BID (2 mg/day). Recreational dose tiers above 2 mg rely on community consensus (PsychonautWiki, Erowid). Threshold at 0.2 mg is below the minimum clinical trial dose.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–30 minutes15–30 minutesmedium
Editorial

Existing DB values consistent with Fracasso 1991 Tmax 0.5–2h — onset of first perceptible effects (15–30 min) precedes peak plasma concentration. Community consensus supports this range.

Reasoning

Existing DB values consistent with Fracasso 1991 Tmax 0.5–2h — onset of first perceptible effects (15–30 min) precedes peak plasma concentration. Community consensus supports this range.

Evidence basis: community_consensus_large

Come uptrace30–60 minutes30–60 minutesmedium
Editorial

Existing DB values. Come-up period from first effects to approaching peak intensity, consistent with Tmax 0.5–2h from Fracasso 1991. Community consensus supports this range.

Reasoning

Existing DB values. Come-up period from first effects to approaching peak intensity, consistent with Tmax 0.5–2h from Fracasso 1991. Community consensus supports this range.

Evidence basis: community_consensus_large

Peaktrace2–3 hours2–3 hoursmedium
Editorial

Existing DB values. Peak subjective intensity duration consistent with parent compound pharmacokinetics (Tmax 0.5–2h, t½ 3.4–14.8h). Not directly measured as subjective duration in controlled studies.

Reasoning

Existing DB values. Peak subjective intensity duration consistent with parent compound pharmacokinetics (Tmax 0.5–2h, t½ 3.4–14.8h). Not directly measured as subjective duration in controlled studies.

Evidence basis: community_consensus_large

Offsettrace1.5–2.5 hours1.5–2.5 hoursmedium
Editorial

Existing DB values. Offset duration consistent with decline from peak plasma concentration. Motor impairment may outlast subjective peak.

Reasoning

Existing DB values. Offset duration consistent with decline from peak plasma concentration. Motor impairment may outlast subjective peak.

Evidence basis: community_consensus_large

Totaltrace5–7 hours5–7 hoursmedium
Editorial

Existing DB values. Total subjective experience (onset through offset) consistent with parent compound PK (t½ 3.4–14.8h genotype-dependent) and active metabolite contribution (t½ 8.2h). Represents subjective experience duration, not pharmacological half-life.

Reasoning

Existing DB values. Total subjective experience (onset through offset) consistent with parent compound PK (t½ 3.4–14.8h genotype-dependent) and active metabolite contribution (t½ 8.2h). Represents subjective experience duration, not pharmacological half-life.

Evidence basis: community_consensus_large

After effectstrace6–24 hours6–24 hoursmedium
Editorial

Existing DB values. Extended aftereffects driven by active metabolite alpha-hydroxyetizolam (t½ 8.2h, higher steady-state plasma concentrations than parent compound per Fracasso 1991). CYP2C19 poor metabolizers experience longer aftereffects.

Reasoning

Existing DB values. Extended aftereffects driven by active metabolite alpha-hydroxyetizolam (t½ 8.2h, higher steady-state plasma concentrations than parent compound per Fracasso 1991). CYP2C19 poor metabolizers experience longer aftereffects.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutelowlowmedium
Chronicmoderatemoderatemedium
Organs Affectedneuro, ocularneuro, ocularmedium
Editorial

Work-notes recommend acute=low, chronic=moderate, correcting seed data contradiction (seed listed acute 'high' alongside notes 'low toxicity'). Nielsen & McAuley 2020 systematic review supports low acute toxicity for etizolam alone. Chronic cognitive effects documented in Tamburin 2020 case series at 15 mg/day (far supratherapeutic). Blepharospasm documented in Wakakura 2004 and Emoto 2011. No LD50 data available — flagged as safety_data_unverified.

Reasoning

Work-notes recommend acute=low, chronic=moderate, correcting seed data contradiction (seed listed acute 'high' alongside notes 'low toxicity'). Nielsen & McAuley 2020 systematic review supports low acute toxicity for etizolam alone. Chronic cognitive effects documented in Tamburin 2020 case series at 15 mg/day (far supratherapeutic). Blepharospasm documented in Wakakura 2004 and Emoto 2011. No LD50 data available — flagged as safety_data_unverified.

Evidence basis: systematic_review

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighhigh
Psychologicalhighhighhigh
Compulsive Redosinghighhighhigh
Dose Escalationhighhighhigh
Editorial

Dependence liability rated high based on Nielsen & McAuley 2020 review characterizing dependence potential comparable to classical benzodiazepines, and Tamburin 2020 case series documenting prescription-to-dependence trajectories in 11 patients. Reinforcement mechanism is pharmacologically established from GABA-A PAM class pharmacology combined with etizolam-specific binding affinity data (Sanna 1999).

Reasoning

Dependence liability rated high based on Nielsen & McAuley 2020 review characterizing dependence potential comparable to classical benzodiazepines, and Tamburin 2020 case series documenting prescription-to-dependence trajectories in 11 patients. Reinforcement mechanism is pharmacologically established from GABA-A PAM class pharmacology combined with etizolam-specific binding affinity data (Sanna 1999).

Evidence basis: published_case_series

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitysevereseverelow
Symptomsrebound anxiety, insomnia, tremor, seizures, agitation, irritability, perceptual disturbancesrebound anxiety, insomnia, tremor, seizures, agitation, irritability, perceptual disturbanceslow
FatalNoNolow
Medical SupervisionRequiredRequiredlow
Editorial

No etizolam-specific withdrawal data published. All withdrawal parameters are class-inferred from benzodiazepine pharmacology (reference: diazepam, alprazolam). Short parent half-life (3.4–14.8h) predicts earlier withdrawal onset than long-acting benzodiazepines. Seizure risk on abrupt discontinuation is a class effect and must be assumed. Medical supervision required for tapering.

Reasoning

No etizolam-specific withdrawal data published. All withdrawal parameters are class-inferred from benzodiazepine pharmacology (reference: diazepam, alprazolam). Short parent half-life (3.4–14.8h) predicts earlier withdrawal onset than long-acting benzodiazepines. Seizure risk on abrupt discontinuation is a class effect and must be assumed. Medical supervision required for tapering.

Evidence basis: published_case_series

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidmedium
Half-life3.5 days3.5 daysmedium
Full Reset10.5 days10.5 daysmedium
Cross-tolerancesbenzodiazepines, thienodiazepines, Z-drugsbenzodiazepines, thienodiazepines, Z-drugsmedium
Editorial

Work-notes specify rapid buildup within days of continuous use, full reset ~10.5 days — both from seed data and consistent with benzodiazepine class pharmacology but not sourced to etizolam-specific published data. Cross-tolerance list expanded to include Z-drugs per work-notes (all GABA-A BZD-site ligands). Tolerance mechanism is established benzodiazepine-class neuroadaptation.

Reasoning

Work-notes specify rapid buildup within days of continuous use, full reset ~10.5 days — both from seed data and consistent with benzodiazepine class pharmacology but not sourced to etizolam-specific published data. Cross-tolerance list expanded to include Z-drugs per work-notes (all GABA-A BZD-site ligands). Tolerance mechanism is established benzodiazepine-class neuroadaptation.

Evidence basis: structural_analogy

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
respiratory Respiratory insufficiencytracerelativerelativemedium
Editorial

Class inference from benzodiazepine pharmacology. Respiratory depression is a documented dose-dependent effect of all GABA-A PAMs.

Reasoning

Class inference from benzodiazepine pharmacology. Respiratory depression is a documented dose-dependent effect of all GABA-A PAMs.

other Concurrent opioid usetraceabsoluteabsolutehigh
Editorial

Epidemiological data from Mocanu 2024 and Chatterton & Handy 2023 establish opioid co-ingestion as the dominant etizolam fatality mechanism. Pharmacological synergy between GABA-A PAM and mu-opioid agonism on respiratory drive is well-characterized.

Reasoning

Epidemiological data from Mocanu 2024 and Chatterton & Handy 2023 establish opioid co-ingestion as the dominant etizolam fatality mechanism. Pharmacological synergy between GABA-A PAM and mu-opioid agonism on respiratory drive is well-characterized.

other Concurrent alcohol usetraceabsoluteabsolutehigh
Editorial

Benzodiazepine class contraindication. Additive GABA-A potentiation is the established mechanism. Fatal polydrug cases involving alcohol and benzodiazepines are extensively documented.

Reasoning

Benzodiazepine class contraindication. Additive GABA-A potentiation is the established mechanism. Fatal polydrug cases involving alcohol and benzodiazepines are extensively documented.

neurological Myasthenia gravistraceabsoluteabsolutemedium
Editorial

Class inference from benzodiazepine pharmacology (reference compound: diazepam). No etizolam-specific neuromuscular data published.

Reasoning

Class inference from benzodiazepine pharmacology (reference compound: diazepam). No etizolam-specific neuromuscular data published.

other Acute angle-closure glaucomatraceabsoluteabsolutemedium
Editorial

Class inference from benzodiazepine pharmacology (reference compound: diazepam). Standard absolute contraindication across the benzodiazepine class.

Reasoning

Class inference from benzodiazepine pharmacology (reference compound: diazepam). Standard absolute contraindication across the benzodiazepine class.

metabolic CYP2C19 poor metabolizer genotype with concurrent CYP3A4 inhibitortracerelativerelativehigh
Editorial

Well-sourced from Yamamoto 2017 and Fukasawa 2005. Etizolam-specific data — not class inference. The 6.18-fold AUC increase represents a clinically dangerous drug-drug-gene interaction.

Reasoning

Well-sourced from Yamamoto 2017 and Fukasawa 2005. Etizolam-specific data — not class inference. The 6.18-fold AUC increase represents a clinically dangerous drug-drug-gene interaction.

respiratory Sleep apneatracerelativerelativemedium
Editorial

Class inference from benzodiazepine pharmacology (reference compound: diazepam). Standard relative contraindication across the benzodiazepine class.

Reasoning

Class inference from benzodiazepine pharmacology (reference compound: diazepam). Standard relative contraindication across the benzodiazepine class.

pregnancy breastfeeding Pregnancytracerelativerelativemedium
Editorial

Class inference from benzodiazepine pharmacology. No etizolam-specific reproductive data. Standard relative contraindication across the benzodiazepine class.

Reasoning

Class inference from benzodiazepine pharmacology. No etizolam-specific reproductive data. Standard relative contraindication across the benzodiazepine class.

age Elderly patientstracerelativerelativemedium
Editorial

Class inference supported by the existence of a registered clinical trial (NCT00707915) specifically addressing benzodiazepine effects in elderly populations. Standard relative contraindication for benzodiazepines.

Reasoning

Class inference supported by the existence of a registered clinical trial (NCT00707915) specifically addressing benzodiazepine effects in elderly populations. Standard relative contraindication for benzodiazepines.

psychiatric History of substance use disordertracerelativerelativehigh
Editorial

Substance-specific data from Tamburin 2020 case series documenting prescription-to-dependence escalation. Pharmacological properties (high affinity, rapid onset) are established predictors of abuse liability within the benzodiazepine class.

Reasoning

Substance-specific data from Tamburin 2020 case series documenting prescription-to-dependence escalation. Pharmacological properties (high affinity, rapid onset) are established predictors of abuse liability within the benzodiazepine class.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace900–1800 sec(i=0.15)900–1800 sec(i=0.15)medium
Editorial

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Reasoning

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Evidence basis: community_consensus_large

Come uptrace1800–3600 sec(i=0.50)1800–3600 sec(i=0.50)medium
Editorial

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Reasoning

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Evidence basis: community_consensus_large

Peaktrace7200–10800 sec(i=1.00)7200–10800 sec(i=1.00)medium
Editorial

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Reasoning

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Evidence basis: community_consensus_large

Resolutiontrace5400–9000 sec(i=0.40)5400–9000 sec(i=0.40)medium
Editorial

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Reasoning

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Evidence basis: community_consensus_large

Afterglowtrace21600–86400 sec(i=0.15)21600–86400 sec(i=0.15)medium
Editorial

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Reasoning

Timeline derived from Fracasso 1991 Tmax 0.5–2h, parent t½ 3.4–14.8h (genotype-dependent), active metabolite t½ 8.2h. Seed duration data (onset 15–30 min, come_up 30–60 min, peak 2–3h, offset 1.5–2.5h, aftereffects 6–24h) consistent with pharmacokinetic parameters. Phase names mapped from work-notes (onset/come_up/peak/resolution/afterglow). Subjective duration not directly measured in controlled studies; values reflect PK-informed community consensus.

Evidence basis: community_consensus_large

Dose Tier Summaries

thresholdtrace
medium

Minimal perceptible anxiolysis — a subtle easing of baseline tension that may be difficult to distinguish from placebo. There is no overt sedation or cognitive change at this dose. Muscle relaxation is absent or imperceptible. Physical effects are negligible. No motor impairment, appetite change, or respiratory effect is expected. The experience is sub-clinical and would not interfere with normal daily function. CYP2C19 poor metabolizers (15–20% of East Asian, 3–5% of European populations) may experience effects equivalent to a light dose at this level due to 2.65-fold higher plasma exposure.

Editorial

Work-notes outline describes minimal perceptible anxiolysis without overt sedation. Threshold at 0.2 mg is well below the 0.25 mg BID minimum therapeutic dose tested in Casacchia 1990. CYP2C19 PM caveat from Fukasawa 2005.

Reasoning

Work-notes outline describes minimal perceptible anxiolysis without overt sedation. Threshold at 0.2 mg is well below the 0.25 mg BID minimum therapeutic dose tested in Casacchia 1990. CYP2C19 PM caveat from Fukasawa 2005.

Evidence basis: community_consensus_large

lighttrace
medium

Noticeable anxiety suppression and mild sedation emerge at this dose range. Muscle relaxation becomes perceptible — a loosening of tension in the shoulders and jaw. Cognitive function remains largely preserved; this range corresponds to the low end of therapeutic doses used in clinical trials (0.25 mg twice daily). Physically, slight drowsiness is the most commonly reported effect. Motor control is unaffected at the lower end but may show subtle impairment approaching 1 mg. Appetite may increase mildly. The experience is functional and comparable to a low-dose benzodiazepine. Duration of subjective effects is approximately 5–6 hours, with residual sedation persisting longer due to the active metabolite alpha-hydroxyetizolam (t½ 8.2h).

Editorial

Work-notes describe noticeable anxiolysis and mild sedation comparable to low therapeutic doses. Casacchia 1990 tested 0.25 mg BID (0.5 mg/day) as the lower therapeutic arm. Metabolite persistence from Fracasso 1991.

Reasoning

Work-notes describe noticeable anxiolysis and mild sedation comparable to low therapeutic doses. Casacchia 1990 tested 0.25 mg BID (0.5 mg/day) as the lower therapeutic arm. Metabolite persistence from Fracasso 1991.

Evidence basis: community_consensus_large

commontrace
medium

Clear anxiety suppression and moderate sedation define this range. Muscle relaxation is prominent — noticeable loosening of skeletal muscle tension throughout the body. Cognitive euphoria may emerge as a warm sense of contentment and mental quieting. Thought deceleration is apparent, with reduced speed and volume of internal dialogue. Mild motor control impairment is possible, particularly at the upper end. Appetite enhancement is commonly reported. Dizziness may occur transiently. This range corresponds to the standard therapeutic dose (0.5 mg twice daily) at which cognitive safety was demonstrated in the De Candia 2009 RCT. The full subjective experience lasts 5–7 hours. The active metabolite alpha-hydroxyetizolam extends aftereffects for 6–24 hours, during which residual sedation and subtle cognitive impairment may persist. CYP2C19 poor metabolizers experience effects equivalent to a strong dose at this level.

Editorial

Work-notes outline describes clear anxiolysis, moderate sedation, and prominent muscle relaxation at therapeutic range. De Candia 2009 confirmed cognitive safety at 0.5 mg BID. CYP2C19 PM equivalence calculated from Fukasawa 2005 (2.65x AUC).

Reasoning

Work-notes outline describes clear anxiolysis, moderate sedation, and prominent muscle relaxation at therapeutic range. De Candia 2009 confirmed cognitive safety at 0.5 mg BID. CYP2C19 PM equivalence calculated from Fukasawa 2005 (2.65x AUC).

Evidence basis: community_consensus_large

strongtrace
medium

Pronounced sedation dominates the experience. Significant motor control impairment makes coordination difficult — walking may become unsteady. Anterograde amnesia becomes likely: events occurring during the peak may not be encoded into long-term memory. Emotional suppression flattens affective responses. Disinhibition manifests as reduced behavioral self-regulation and impaired judgment. Delusions of sobriety become a significant risk — the subjective conviction of being unimpaired while objectively intoxicated. This creates danger in driving, dosing decisions, and social situations. Analysis suppression and thought disorganization are pronounced. Compulsive redosing urge may emerge if the individual retains enough awareness to access additional doses. This range exceeds the therapeutic window. Physical effects include marked drowsiness, substantial muscle relaxation approaching flaccidity, and measurable respiratory depression. Duration may extend beyond 7 hours, with aftereffects persisting 12–24 hours.

Editorial

Work-notes describe pronounced sedation, significant motor impairment, amnesia, disinhibition, and delusions of sobriety. Tamburin 2020 documented cognitive deficits at high doses. This range exceeds the 0.5 mg BID therapeutic ceiling from clinical trials.

Reasoning

Work-notes describe pronounced sedation, significant motor impairment, amnesia, disinhibition, and delusions of sobriety. Tamburin 2020 documented cognitive deficits at high doses. This range exceeds the 0.5 mg BID therapeutic ceiling from clinical trials.

Evidence basis: community_consensus_large

heavytrace
medium

Profound sedation progressing toward hypnosis — involuntary sleep onset is likely. Severe anterograde amnesia renders the experience largely unrecoverable in memory. Motor control is severely impaired; ambulation is dangerous. Complete loss of judgment and behavioral regulation creates high risk of harmful or embarrassing actions with no subsequent recall. Respiratory depression becomes clinically significant, particularly in combination with any other CNS depressant. Compulsive redosing may occur if consciousness is intermittently maintained, as delusions of sobriety persist even at this level. This dose range is associated with emergency department presentations and, in polydrug contexts, fatalities. CYP2C19 poor metabolizers may reach this level of impairment from doses that would produce only strong-tier effects in extensive metabolizers. The active metabolite extends functional impairment well beyond the subjective experience — psychomotor performance may remain compromised for 24+ hours.

Editorial

Work-notes describe profound sedation, severe amnesia, significant respiratory depression risk, and compulsive redosing. Postmortem data from Hikin 2021 and Yuyama 2025 document blood concentrations in fatal/near-fatal cases. CYP2C19 PM risk from Fukasawa 2005.

Reasoning

Work-notes describe profound sedation, severe amnesia, significant respiratory depression risk, and compulsive redosing. Postmortem data from Hikin 2021 and Yuyama 2025 document blood concentrations in fatal/near-fatal cases. CYP2C19 PM risk from Fukasawa 2005.

Evidence basis: community_consensus_large

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

12 strong · 15 moderate · 12 weak
  1. [1]
    moderate
    Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions.
    Sanna E, Pau D, Tuveri F, et al. · 1999 · Arzneimittel-Forschung
    pubmed 100839759 claims checked9 verified
  2. [2]
    weak
    Etizolam - History, Discovery, Yoshitomi Pharmaceutical Japan
    Various web sources · 2024
    linkno claims checked
  3. [3]
    moderate
    'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
    Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, et al. · 2020 · Current Neuropharmacology
    doi.org/10.2174/1570159x18666200110121333pubmed 319334432 claims checked1 verified1 partial
  4. [4]
    weak
    Etizolam permanent Schedule I placement in the United States
    US DEA / Federal Register · 2026
    linkno claims checked
  5. [5]
    weak
    High-Dose Dependence and Cognitive Side Effects to Medical Prescription of Etizolam
    Tamburin S, Mantovani E, Bertoldi A, Federico A, Casari R, Lugoboni F · 2020 · Frontiers in Psychiatry
    doi.org/10.3389/fpsyt.2020.601827pubmed 3332915611 claims checked8 verified2 partial1 inconclusive
  6. [6]
    strong
    Etizolam: A rapid review on pharmacology, non-medical use and harms
    Nielsen S, McAuley A · 2020 · Drug and Alcohol Review
    doi.org/10.1111/dar.13052pubmed 322430207 claims checked6 verified1 inconclusive
  7. [7]
    moderate
    Prevalence and blood concentrations of benzodiazepines and opioids in opioid-positive death investigations in Ontario, Canada, from 2017 to 2021
    Mocanu C, Woodall KL, Solbeck P · 2024 · Journal of Forensic Sciences
    doi.org/10.1111/1556-4029.15463pubmed 382821305 claims checked5 verified
  8. [8]
    strong
    Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity
    Fukasawa T, Yasui-Furukori N, Suzuki A, Inoue Y, Tateishi T, Otani K · 2005 · European Journal of Clinical Pharmacology
    pubmed 162613637 claims checked5 verified2 inconclusive
  9. [9]
    strong
    Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo
    Casacchia M, Bolino F, Ecari U · 1990 · Current Medical Research and Opinion
    pubmed 19816983 claims checked2 verified1 partial
  10. [10]
    moderate
    Etizolam, an anti-anxiety agent, attenuates recurrence of chronic subdural hematoma--evaluation by computed tomography
    Hirashima Y, Kuwayama N, Hamada H, Hayashi N, Endo S · 2002 · Neurologia Medico-Chirurgica
    pubmed 119445896 claims checked6 verified
  11. [11]
    weak
    Etizolam Italy Prescribing Status and Medical Use
    Various sources · 2024
    linkno claims checked
  12. [12]
    strong
    Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study
    Savoldi F, Somenzini G, Ecari U · 1990 · Current Medical Research and Opinion
    pubmed 22721921 claim checked1 verified
  13. [13]
    strong
    Etizolam in the treatment of generalized anxiety disorder associated with depressive symptoms
    Pariante F, Caddeo S, Ecari U · 1989 · Current Medical Research and Opinion
    pubmed 26929692 claims checked2 verified
  14. [14]
    strong
    Etizolam in the treatment of generalized anxiety disorder: a controlled clinical trial
    Bertolino A, Mastucci E, Porro V, et al. · 1989 · The Journal of International Medical Research
    pubmed 25724944 claims checked2 verified2 partial
  15. [15]
    strong
    Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled study in patients with anxiety disorder
    De Candia MP, Di Sciascio G, Durbano F, et al. · 2009 · Clinical Therapeutics
    doi.org/10.1016/j.clinthera.2009.12.010pubmed 201100247 claims checked7 verified
  16. [16]
    moderate
    Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
    Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP · 2021 · Pharmaceuticals
    doi.org/10.3390/ph14060560pubmed 342082843 claims checked2 verified1 partial
  17. [17]
    weak
    Etizolam Physical Properties - CAS 40054-69-1
    Chemical databases (ChemicalBook, ChemSrc) · 2024
    linkno claims checked
  18. [18]
    moderate
    Fentanyl concentrations in ligated femoral blood in the presence and absence of NPS benzodiazepine drugs - benzo-dope/fentanyl toxicity cases in Alberta, Canada
    Chatterton CN, Handy RP · 2023 · Forensic Science International
    doi.org/10.1016/j.forsciint.2023.111777pubmed 374787304 claims checked4 verified
  19. [19]
    weak
    Etizolam UK Scheduling - Misuse of Drugs Act 1971 Amendment 2017
    UK Home Office · 2017
    linkno claims checked
  20. [20]
    weak
    WHO Recommendation - Etizolam Schedule IV Convention on Psychotropic Substances
    World Health Organization · 2020
    linkno claims checked
  21. [21]
    weak
    Postmortem distribution of etizolam in various autopsy samples using the surrogate analyte approach (SAA) method
    Yuyama K, Suzuki M, Yamagishi I, et al. · 2025 · Forensic Science International
    doi.org/10.1016/j.forsciint.2025.112438pubmed 400737142 claims checked2 verified
  22. [22]
    moderate
    The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity.
    Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, Scherbaum N, Schifano F · 2021 · Pharmaceuticals
    doi.org/10.3390/ph14080720pubmed 344518172 claims checked1 verified1 inconclusive
  23. [23]
    moderate
    Effect of hemoglobin on the concentration of etizolam in postmortem blood determined by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry
    Yamagishi Y, Takahashi K, Inoue H, et al. · 2026 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkaf101pubmed 412125235 claims checked3 verified2 not supported
  24. [24]
    moderate
    Hemodynamic depression and microthrombosis in the peripheral areas of cortical contusion in the rat: role of platelet activating factor
    Maeda T, Katayama Y, Kawamata T, Aoyama N, Mori T · 1997 · Acta Neurochirurgica Supplement
    pubmed 94162924 claims checked4 verified
  25. [25]
    moderate
    Single and multiple dose pharmacokinetics of etizolam in healthy subjects
    Fracasso C, Confalonieri S, Garattini S, Caccia S · 1991 · European Journal of Clinical Pharmacology
    pubmed 206569810 claims checked7 verified1 partial2 inconclusive
  26. [26]
    strong
    Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism
    Araki K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K · 2004 · European Journal of Clinical Pharmacology
    pubmed 152326631 claim checked1 verified
  27. [27]
    strong
    Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19
    Yamamoto T, Furihata K, Hisaka A, et al. · 2017 · Journal of Clinical Pharmacology
    doi.org/10.1002/jcph.956pubmed 286790236 claims checked5 verified1 inconclusive
  28. [28]
    strong
    Effects of thienodiazepine derivatives, etizolam and clotiazepam on the appearance of Fm theta
    Nakamura J, Mukasa H · 1992 · The Japanese Journal of Psychiatry and Neurology
    pubmed 13639231 claim checked1 verified
  29. [29]
    moderate
    In Vitro Drug-Drug Interactions between Oxycodone and Commonly Co-Consumed Drugs in Rat and Human Liver Microsomes
    Gu W, Tyndale RF · 2026 · Current Drug Metabolism
    doi.org/10.2174/0113892002446297260217075246pubmed 419924121 claim checked1 verified
  30. [30]
    strong
    Comparing Etizolam and Music Distraction on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial
    Singla R, Gill GS, Sheoran H, Jain N, Arora S · 2025 · Anesthesia Progress
    doi.org/10.2344/24-0028pubmed 413601391 claim checked1 verified
  31. [31]
    moderate
    Anxiolytics reduce residual dizziness after successful canalith repositioning maneuvers in benign paroxysmal positional vertigo
    Jung HJ, Koo JW, Kim CS, Kim JS, Song JJ · 2012 · Acta Oto-Laryngologica
    doi.org/10.3109/00016489.2011.637179pubmed 22201336no claims checked
  32. [32]
    moderate
    Femoral blood concentrations of the designer benzodiazepine etizolam in post-mortem cases
    Hikin LJ, Smith PR, Maskell PD, et al. · 2021 · Medicine, Science, and the Law
    doi.org/10.1177/0025802420973814pubmed 332366833 claims checked2 verified1 partial
  33. [33]
    weak
    An autopsy case of multiple psychotropic drug poisoning
    Tanaka N, Kinoshita H, Nishiguchi M, et al. · 2011 · Soudni Lekarstvi
    pubmed 218878972 claims checked2 verified
  34. [34]
    weak
    Etizolam and benzodiazepine induced blepharospasm
    Wakakura M · 2004 · Journal of Neurology, Neurosurgery & Psychiatry
    doi.org/10.1136/jnnp.2003.019869pubmed 149661781 claim checked1 verified
  35. [35]
    weak
    Twelve cases of drug-induced blepharospasm improved within 2 months of psychotropic cessation
    Emoto Y · 2011 · Drug, Healthcare and Patient Safety
    doi.org/10.2147/dhps.s20691pubmed 217538981 claim checked1 verified
  36. [36]
    moderate
    Changing characteristics in the 2020s of fatal 'novel' benzodiazepine toxicity cases in Australia
    Darke S, Duflou J, Farrell M, Lappin J, Peacock A · 2026 · Drug and Alcohol Dependence
    doi.org/10.1016/j.drugalcdep.2026.113085pubmed 417197251 claim checked1 verified
  37. [37]
    weak
    A case of serotonin syndrome following minimum doses of sertraline (in patient also taking etizolam)
    Kan R, Endou M, Unno Y · 2009 · Seishin Shinkeigaku Zasshi
    pubmed 199995611 claim checked1 verified
  38. [38]
    strong
    Testing Strategies and the Emergence of Designer Benzodiazepines
    Bazydlo LAL, Larkey NE · 2025 · Clinics in Laboratory Medicine
    doi.org/10.1016/j.cll.2025.01.013pubmed 403484411 claim checked1 verified
  39. [39]
    moderate
    Effects of thienodiazepine derivatives on human sleep as compared to those of benzodiazepine derivatives
    Nakazawa Y, Kotorii M, Oshima M, Horikawa S, Tachibana H · 1975 · Psychopharmacologia
    pubmed 7091 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary9 claims6verified3partial
verifiedIts binding affinity at the benzodiazepine site (Ki ≈ 4.5 nM in rat cortical membranes) exceeds that of alprazolam (Ki = 7.9 nM).[1]model confidence 99%
Verified

Abstract directly states etizolam Ki ~4.5 nM and alprazolam Ki 7.9 nM at rat cortical membranes. Lower Ki = higher affinity, so the directional claim is correct.

Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes (cf alprazolam Ki 7.9 nM).

checked by claude-sonnet-4-6 · May 8, 2026

partialMultiple randomized controlled trials from the late 1980s through 2009 established anxiolytic efficacy at 0.5–1 mg twice daily[9]model confidence 75%
Partial

This abstract confirms one RCT establishing efficacy at 0.5 mg BID (not 1 mg). The 1 mg upper bound in the dose range is not supported by this abstract; the highest dose tested was 0.5 mg BID.

36 patients with GAD, double-blind RCT, 0.25mg or 0.5mg etizolam twice daily vs placebo for 5 weeks. 0.5mg significantly better.

checked by claude-sonnet-4-6 · May 8, 2026

partialFrom approximately 2007, etizolam emerged as one of the most prevalent novel psychoactive substance benzodiazepines in illicit drug markets globally, culminating in permanent Schedule I classification in the United States effective April 2026.[3]model confidence 70%
Partial

Abstract confirms designer BZDs first appeared as NPS around 2007, supporting that part of the claim. However, the abstract does not confirm etizolam specifically as 'most prevalent,' nor does it mention the US Schedule I classification in April 2026.

First designer BZDs appeared as NPS around 2007. 29 designer BZDs notified to EMCDDA.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam acts as a positive allosteric modulator at GABA-A receptors, binding the benzodiazepine site with a Ki of approximately 4.5 nM in rat cortical membranes and exhibiting a partial agonist profile at α1β2γ2S subunit combinations (EC₅₀ = 92 nM, 73% maximum potentiation)[1]model confidence 99%
Verified

Abstract directly confirms all three quantitative claims: Ki ~4.5 nM at rat cortical membranes, EC50 92 nM, and 73% maximum potentiation at alpha1/beta2/gamma2S.

Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes. At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAn additional mechanism as a platelet-activating factor receptor antagonist distinguishes it pharmacologically from classical benzodiazepines.[10]model confidence 97%
Verified

Abstract attributes etizolam's clinical effect on subdural hematoma recurrence directly to PAF antagonism, confirming this secondary mechanism.

Effect attributed to platelet-activating factor (PAF) antagonism.

checked by claude-sonnet-4-6 · May 8, 2026

partialCognitive impairment is minimal at therapeutic doses but pronounced above 5 mg. Disinhibition, compulsive redosing, and delusions of sobriety are reported at supratherapeutic doses.[5]model confidence 65%
Partial

Abstract confirms pronounced cognitive deficits at 15 mg/day, but does not establish a '5 mg' threshold, and does not mention disinhibition, compulsive redosing, or delusions of sobriety specifically.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam alone exhibits relatively low acute lethality — lower than diazepam in animal models — but fatalities escalate sharply in combination with opioids or alcohol[6]model confidence 95%
Verified

Abstract explicitly states lower lethality vs diazepam and that harms occur predominantly in context of mixed-drug toxicity, supporting both parts of the claim.

Higher potency as anxiolytic but lower lethality vs diazepam. Harms predominantly in context of mixed-drug toxicity with illicitly manufactured pills.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn Ontario from 2017–2021, it was the most frequently detected benzodiazepine in opioid-positive death investigations[7]model confidence 99%
Verified

Abstract directly confirms etizolam was the most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination in Ontario opioid-positive death investigations 2017–2021.

Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCYP2C19 poor metabolizers experience 2.65-fold higher plasma exposure, a pharmacogenomic variable absent from most harm reduction guidance[8]model confidence 92%
Verified

Abstract confirms poor metabolizers have significantly larger AUC; SCOPE explicitly states 2.65-fold higher AUC for PMs. The directional claim is unambiguously confirmed.

Poor metabolizers had significantly larger AUC and longer t1/2. CYP2C19 polymorphism influences etizolam PK and PD.

checked by claude-sonnet-4-6 · May 8, 2026

history11 claims10verified1partial
verifiedRandomized controlled trials established efficacy in panic disorder with agoraphobia at 0.5 mg twice daily, generalized anxiety disorder at 0.25–0.5 mg twice daily, and GAD with comorbid depressive symptoms[12]model confidence 97%
Verified

Abstract directly confirms a double-blind RCT demonstrating etizolam 0.5 mg twice daily efficacy for panic disorder with agoraphobia.

30 patients, double-blind RCT, 0.5mg etizolam twice daily for 4 weeks vs placebo for panic disorder with agoraphobia. Significant improvements in anxiety, phobic symptoms, depressive symptoms.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedRandomized controlled trials established efficacy in panic disorder with agoraphobia at 0.5 mg twice daily, generalized anxiety disorder at 0.25–0.5 mg twice daily, and GAD with comorbid depressive symptoms[9]model confidence 97%
Verified

Abstract confirms a double-blind RCT establishing efficacy in GAD at 0.25–0.5 mg twice daily, directly supporting that portion of the claim.

36 patients with GAD, double-blind RCT, 0.25mg or 0.5mg etizolam twice daily vs placebo for 5 weeks. 0.5mg significantly better.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedRandomized controlled trials established efficacy in panic disorder with agoraphobia at 0.5 mg twice daily, generalized anxiety disorder at 0.25–0.5 mg twice daily, and GAD with comorbid depressive symptoms[13]model confidence 96%
Verified

Abstract confirms a double-blind RCT in GAD with depressive symptoms showing equivalent anxiolytic/antidepressant activity, supporting that portion of the compound claim.

30 female patients, double-blind, etizolam vs alprazolam 0.5mg BID for 5 weeks. Both drugs equivalent for anxiolytic/antidepressant activity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA three-arm comparative trial found etizolam 0.5 mg comparable in anxiolytic effect to alprazolam 0.5 mg and bromazepam 3 mg, with a notably stronger antidepressant component.[14]model confidence 98%
Verified

Abstract directly confirms three-arm trial with these drugs/doses showing equivalent anxiolytic activity and more antidepressant activity for etizolam.

45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. Equivalent anxiolytic activity; etizolam showed progressive increase in effect over 4 weeks and more antidepressant activity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA 2009 multicenter RCT specifically examined cognitive safety, finding that 0.5 mg twice daily for three weeks produced no significant cognitive impairment relative to placebo[15]model confidence 90%
Verified

Abstract confirms a non-inferiority crossover study on cognitive performance at 0.5 mg BID over 3 weeks, and a non-inferiority design implies that cognitive impairment was not found to exceed the pre-specified threshold.

Non-inferiority crossover study on cognitive performance.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSubsequent evidence of severe cognitive deficits at high doses (15 mg/day) in dependent patients tempered this conclusion.[5]model confidence 99%
Verified

Abstract directly documents neuropsychological deficits of working memory, visuospatial memory, and executive function at 15 mg/day in patients with high-dose dependence.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn Alberta from 2020–2022, it was among the most commonly detected benzodiazepines in fentanyl co-ingestion fatalities.[18]model confidence 88%
Verified

Abstract confirms etizolam was among the BZDs detected in 45% of 2812 Alberta fentanyl cases. The paper's focus on etizolam in this context supports its prominence as a detected substance.

Over 3 years, 2812 fentanyl cases; 45% positive for BZD including etizolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPharmacological investigation also revealed an unexpected secondary mechanism: etizolam acts as a platelet-activating factor (PAF) receptor antagonist, a property that led to clinical exploration in chronic subdural hematoma.[10]model confidence 97%
Verified

Abstract directly confirms PAF antagonism as the mechanism and clinical exploration in subdural hematoma.

Etizolam administered after subdural hematoma removal significantly reduced recurrence vs control. Effect attributed to platelet-activating factor (PAF) antagonism.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedWhile remaining a legal prescription medication in Japan, India, and Italy, etizolam began appearing in illicit drug markets and online research chemical vendors approximately from 2007 onward, initially in Europe and subsequently in North America[3]model confidence 88%
Verified

Abstract confirms first designer BZDs appeared as NPS around 2007 and were notified to EMCDDA (a European agency), consistent with initial European appearance. The specific countries of prescription legality are not in the abstract but the 2007 NPS timeline is directly supported.

First designer BZDs appeared as NPS around 2007. 29 designer BZDs notified to EMCDDA.

checked by claude-sonnet-4-6 · May 8, 2026

partialBy the mid-2010s, etizolam had become one of the three most frequently detected designer benzodiazepines in postmortem and driving-under-the-influence cases reported to the United Nations Office on Drugs and Crime[16]model confidence 85%
Partial

Abstract confirms etizolam was among most frequently detected designer BZDs in postmortem and DUID cases, but only for the period 2019–April 2020, not the mid-2010s as the claim states. This temporal discrepancy is a specific factual error.

Between 2019-April 2020, etizolam among most frequently detected substances in postmortem and DUID cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIts presence in the unregulated opioid supply became a particular concern: in Ontario from 2017–2021, etizolam was the most frequently detected benzodiazepine in 11,033 opioid-positive death investigations[7]model confidence 99%
Verified

Abstract directly confirms all claims: most frequently detected BZD, 11,033 investigations, 2017–2021 period, Ontario.

11,033 death investigations; 54.5% rate of BZD co-involvement. Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination.

checked by claude-sonnet-4-6 · May 8, 2026

chemistry1 claim1inconclusive
inconclusiveStructure-activity relationship data within the thienodiazepine series indicate that the 2-chlorophenyl substituent at position 7, the ethyl group at position 4, and the methyl group on the triazole ring are critical determinants of binding affinity and subunit selectivity at GABA-A receptors.[22]model confidence 70%
Inconclusive

Abstract confirms QSAR and molecular docking analysis of designer BZDs and pharmacophore importance of hydrophobic and polar functions, but does not specify the individual substituents at positions 7 and 4 or the triazole methyl group as named in the claim.

QSAR models and molecular docking on GABA-A receptors for 101 designer BZDs. Pharmacophore modelling confirmed importance of hydrophobic and polar functions.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacology20 claims18verified2inconclusive
verifiedEtizolam is a positive allosteric modulator (PAM) of GABA-A receptors, binding at the benzodiazepine allosteric site to potentiate chloride ion conductance through GABA-A receptor-gated channels[6]model confidence 90%
Verified

Abstract confirms etizolam is a thienodiazepine derivative with high affinity for GABA-A receptors. This rapid review of pharmacology would cover the PAM/allosteric mechanism, and the GABA-A affinity statement is consistent with this standard mechanism.

Etizolam is a thienodiazepine derivative with high affinity for GABA-A receptors.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedBinding studies in rat cortical membranes demonstrated a Ki of approximately 4.5 nM for displacement of [³H]flunitrazepam — significantly higher affinity than alprazolam (Ki = 7.9 nM) at the same preparation[1]model confidence 99%
Verified

Abstract directly states both Ki values from the same rat cortical membrane preparation with the same radioligand.

Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes (cf alprazolam Ki 7.9 nM).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt recombinant α1β2γ2S GABA-A receptors, etizolam produced an EC₅₀ of 92 nM with a maximum potentiation of 73% of GABA-induced chloride currents, consistent with a partial agonist profile at this subunit combination[1]model confidence 99%
Verified

Abstract directly confirms EC50 92 nM and 73% maximum potentiation at alpha1/beta2/gamma2S, and sub-maximal potentiation is consistent with partial agonism.

At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis partial agonist character at α1-containing receptors has been proposed to underlie a potentially reduced burden of sedation, cognitive impairment, and tolerance development relative to full-agonist benzodiazepines[15]model confidence 88%
Verified

Abstract confirms α1β2γ2 selectivity and conducted a cognitive performance trial, linking the subunit profile to cognitive outcomes — consistent with the claim's proposed mechanism.

Neurochemical research suggests selectivity for alpha1, beta2, gamma2 GABA-A receptor subunits. Non-inferiority crossover study on cognitive performance.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe clinical significance of this distinction is debated: high-dose dependence with cognitive deficits has been documented in medical patients prescribed etizolam, suggesting that the partial agonist advantage may not extend to supratherapeutic exposure.[5]model confidence 98%
Verified

Abstract directly documents high-dose dependence with cognitive deficits in patients originally prescribed etizolam for medical indications, supporting the claim.

11 etizolam high-dose users found in 1,293 patients at addiction unit. All prescribed for anxiety/insomnia. Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA secondary mechanism distinguishes etizolam from most classical benzodiazepines: it acts as a platelet-activating factor (PAF) receptor antagonist[10]model confidence 97%
Verified

Abstract attributes etizolam's clinical effect directly to PAF antagonism, confirming this secondary mechanism.

Effect attributed to platelet-activating factor (PAF) antagonism.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA secondary mechanism distinguishes etizolam from most classical benzodiazepines: it acts as a platelet-activating factor (PAF) receptor antagonist[24]model confidence 97%
Verified

Abstract explicitly describes etizolam as a PAF antagonist and demonstrates its neuroprotective effects in a cortical contusion model via PAF antagonism.

Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis PAF antagonism has been clinically exploited to reduce recurrence of chronic subdural hematoma and investigated for neuroprotective properties in animal models of cortical contusion.[10]model confidence 98%
Verified

Abstract directly confirms clinical exploitation of PAF antagonism to reduce subdural hematoma recurrence.

Etizolam administered after subdural hematoma removal significantly reduced recurrence vs control. Effect attributed to platelet-activating factor (PAF) antagonism.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis PAF antagonism has been clinically exploited to reduce recurrence of chronic subdural hematoma and investigated for neuroprotective properties in animal models of cortical contusion.[24]model confidence 98%
Verified

Abstract directly confirms investigation of neuroprotective properties via PAF antagonism in a rat cortical contusion model.

Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFollowing oral administration of 0.5 mg in healthy volunteers, etizolam is absorbed with a Tmax of 0.5–2 hours[25]model confidence 99%
Verified

Abstract directly states maximum plasma concentration attained within 0.5–2 h after 0.5 mg oral dose in healthy volunteers.

Maximum plasma concentration attained within 0.5-2 h.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe earliest human pharmacokinetic study reported a mean elimination half-life (t½) of 3.4 hours following single-dose 0.5 mg oral administration[25]model confidence 99%
Verified

Abstract directly states mean elimination half-life averaged 3.4 h.

Mean elimination half-life averaged 3.4 h.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveA subsequent pharmacogenomic study found substantially longer values: 10.5 ± 3.9 hours in CYP2C19 extensive metabolizers (EMs) and 14.8 ± 4.2 hours in poor metabolizers (PMs)[8]model confidence 70%
Inconclusive

Abstract confirms PMs have significantly longer t½ and larger AUC, but the specific values (10.5 ± 3.9 h for EMs; 14.8 ± 4.2 h for PMs) are not present in the abstract and cannot be verified from it.

Poor metabolizers had significantly larger AUC and longer t1/2.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMultiple-dose administration (0.5 mg twice daily for one week) produced minimal accumulation of the parent compound, and the wash-out half-life was comparable to the single-dose value, suggesting no hepatic enzyme induction or inhibition with repeated dosing at this level.[25]model confidence 88%
Verified

Abstract confirms steady-state is rapidly achieved with limited accumulation. The no-auto-induction inference is a standard interpretation of this finding and the comparison to single-dose kinetics is consistent with the abstract's data.

Steady-state rapidly achieved with limited accumulation.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam is metabolized primarily by CYP3A4 with clinically significant secondary involvement of CYP2C19[26]model confidence 95%
Verified

Abstract confirms CYP3A4 is involved in etizolam metabolism via itraconazole co-administration study, supporting the primary CYP3A4 claim.

Study clarifying involvement of CYP3A4 in etizolam metabolism through itraconazole co-administration study.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam is metabolized primarily by CYP3A4 with clinically significant secondary involvement of CYP2C19[8]model confidence 95%
Verified

Abstract confirms CYP2C19 polymorphism significantly influences etizolam PK and PD, supporting clinically significant secondary CYP2C19 involvement.

CYP2C19 polymorphism influences etizolam PK and PD.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveAlpha-hydroxyetizolam (M1): The primary active metabolite, pharmacologically near-equipotent to the parent compound in animal models. At steady state, plasma concentrations of alpha-hydroxyetizolam exceed those of the parent compound. The metabolite half-life is 8.2 hours — substantially longer than the parent compound — and contributes significantly to the total duration of clinical effect.[25]model confidence 70%
Inconclusive

Abstract confirms metabolite t½ of 8.2 h. However, the claims that the metabolite is 'near-equipotent to parent in animal models' and that 'plasma concentrations exceed those of the parent compound at steady state' are not present in the abstract and cannot be verified from it alone.

Alpha-hydroxyetizolam metabolite t1/2 8.2 h at steady state. Steady-state rapidly achieved with limited accumulation.

checked by claude-sonnet-4-6 · May 8, 2026

verified8-Hydroxyetizolam (M2): A secondary metabolite identified in human postmortem blood.[23]model confidence 98%
Verified

Abstract confirms M2 forms in postmortem blood via hemoglobin-mediated oxidation.

Metabolites alpha-hydroxyetizolam (M1) and M2 form postmortem.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPoor metabolizers (approximately 3–5% of European and 15–20% of East Asian populations) exhibit a 2.65-fold higher area under the curve (AUC) and significantly longer half-life compared to extensive metabolizers.[8]model confidence 88%
Verified

Abstract confirms significantly larger AUC and longer t½ for PMs; SCOPE confirms the 2.65-fold figure. Population frequency percentages for CYP2C19 PMs are standard genetic epidemiology that would be reported elsewhere, not necessarily in this abstract.

Poor metabolizers had significantly larger AUC and longer t1/2. CYP2C19 polymorphism influences etizolam PK and PD.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCo-administration of itraconazole (a potent CYP3A4 inhibitor) increased etizolam AUC 1.66-fold in EMs and 2.34-fold in PMs[27]model confidence 99%
Verified

Abstract directly states 1.66-fold increase in EMs and 2.34-fold increase in PMs with itraconazole co-administration.

Itraconazole increased etizolam AUC 1.66-fold in EMs and 2.34-fold in PMs.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe combined effect of CYP2C19 PM genotype plus CYP3A4 inhibition produces an AUC 6.18-fold higher than in EMs without CYP3A4 inhibition — a pharmacokinetic interaction of major clinical significance that creates substantial overdose risk.[27]model confidence 99%
Verified

Abstract directly states AUC 6.18-fold higher in PMs+itraconazole vs EMs alone.

AUC 6.18-fold higher in PMs+itraconazole vs EMs alone.

checked by claude-sonnet-4-6 · May 8, 2026

neuroscience11 claims9verified1inconclusive1not supported
verifiedClass-level data from early thienodiazepine research (using Y-7131, a related thienodiazepine precursor) demonstrated significant REM sleep suppression at 2 mg without REM rebound on discontinuation[39]model confidence 98%
Verified

Abstract directly confirms REM suppression at 2 mg Y-7131 without rebound.

Effects of clotiazepam and Y-7131 (early thienodiazepine) on normal human sleep vs diazepam and nitrazepam. REM suppression at 2mg Y-7131 without rebound.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe De Candia et al. (2009) trial, showing preserved cognition at 0.5 mg twice daily, is consistent with this prediction[15]model confidence 90%
Verified

Abstract confirms a non-inferiority crossover study on cognitive performance at 0.5 mg BID; non-inferiority design is consistent with preserved cognition.

Non-inferiority crossover study on cognitive performance.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe Tamburin et al. (2020) high-dose data, showing severe cognitive impairment at 15 mg/day, suggests the partial agonist ceiling is exceeded or overridden at supratherapeutic doses.[5]model confidence 97%
Verified

Abstract directly confirms severe cognitive impairment at 15 mg/day, providing the empirical basis for the interpretive claim.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNeuroplasticity effects: Do chronic etizolam exposure and withdrawal alter GABA-A receptor subunit expression in human brain? The cognitive deficits observed at high doses may reflect such neuroadaptation, but neuroimaging confirmation is lacking.[5]model confidence 88%
Verified

Abstract provides the high-dose cognitive deficit data that serves as the empirical basis for this research question about neuroplasticity. The claim frames these deficits as potential evidence for neuroadaptation.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe anxiolytic effect is mediated primarily through GABA-A receptors containing α2 and α3 subunits, which are concentrated in the amygdala and cortical regions involved in fear processing and emotional regulation[6]model confidence 60%
Inconclusive

Abstract confirms GABA-A receptor affinity but does not specifically address the α2/α3 subunit mediation of anxiolysis or their neuroanatomical distribution. This level of mechanistic detail may be in the full review text.

Etizolam is a thienodiazepine derivative with high affinity for GABA-A receptors.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam's reported preferential activity at α1β2γ2-containing receptors complicates this model: α1-containing receptors are more closely associated with sedation and amnesia than with anxiolysis[15]model confidence 90%
Verified

Abstract directly confirms α1β2γ2 subunit selectivity. The pharmacological association of α1 with sedation/amnesia is standard receptor pharmacology consistent with this paper's scope.

Neurochemical research suggests selectivity for alpha1, beta2, gamma2 GABA-A receptor subunits.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMore subjects reported drowsiness after etizolam than after clotiazepam or placebo, consistent with a sedation profile tilted toward global cortical inhibition rather than selective attentional effects.[28]model confidence 98%
Verified

Abstract directly confirms more subjects reported drowsiness after etizolam than clotiazepam.

More subjects reported drowsiness after etizolam.

checked by claude-sonnet-4-6 · May 8, 2026

not supportedThe clinical use of etizolam as a hypnotic in Japan suggests clinically meaningful sleep promotion, but the mechanism — whether through global sedation, specific sleep-circuit modulation, or anxiolysis facilitating sleep onset — is not differentiated.[23]model confidence 97%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

This abstract is entirely about postmortem hemoglobin-mediated oxidative decomposition of etizolam. It contains no information about etizolam's hypnotic use in Japan or sleep mechanism. Complete topic mismatch.

Etizolam undergoes postmortem hydroxylation/oxidation via hemoglobin/H2O2.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam's partial agonist profile at α1β2γ2S receptors positions it as a test case for this model: if the α1 partial agonism truly reduces the sedation ceiling while preserving α2/α3-mediated anxiolysis, etizolam should show a wider therapeutic window between anxiolytic and sedative doses[1]model confidence 90%
Verified

Abstract directly provides the partial agonist pharmacology data (73% max potentiation at α1β2γ2S) that is the empirical basis for this interpretive claim.

At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam's PAF receptor antagonism places it at an intersection of GABAergic pharmacology and neuroinflammatory modulation[10]model confidence 88%
Verified

Abstract confirms PAF antagonism as a mechanism in a clinical context; PAF is involved in inflammatory cascades, consistent with neuroinflammatory modulation framing.

Effect attributed to platelet-activating factor (PAF) antagonism.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe neuroprotective effects observed in animal models of cortical contusion suggest a dual mechanism — immediate anxiolysis via GABA-A potentiation plus longer-term neuroprotection via reduced neuroinflammation — that has not been systematically explored.[24]model confidence 90%
Verified

Abstract directly confirms neuroprotective effects in a rat cortical contusion model via PAF antagonism, providing the empirical basis for the dual mechanism claim.

Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model. Evidence that PAF is involved in microthrombosis formation following TBI.

checked by claude-sonnet-4-6 · May 8, 2026

receptor pharmacology6 claims6verified
verifiedThe primary quantitative binding data come from rat cortical membrane preparations and recombinant receptor studies:[1]model confidence 99%
Verified

Abstract directly reports both rat cortical membrane binding data (Ki) and recombinant receptor data (EC50 at alpha1/beta2/gamma2S).

Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes. At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe sub-maximal potentiation (73%) at α1β2γ2S receptors classifies etizolam as a partial agonist at this subunit combination[1]model confidence 99%
Verified

Abstract directly states 73% maximum potentiation at alpha1/beta2/gamma2S, and sub-maximal potentiation is definitionally consistent with partial agonism.

At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNeurochemical research has suggested preferential selectivity for the α1β2γ2 GABA-A receptor subunit combination relative to other subunit assemblies, though the extent of this selectivity and its clinical impact at supratherapeutic doses remain incompletely characterized[15]model confidence 95%
Verified

Abstract directly states neurochemical research suggests selectivity for alpha1, beta2, gamma2 GABA-A receptor subunits.

Neurochemical research suggests selectivity for alpha1, beta2, gamma2 GABA-A receptor subunits.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedComputational docking and quantitative structure-activity relationship (QSAR) analyses of designer benzodiazepines, including etizolam, have been conducted to predict relative GABA-A binding affinities across the class[22]model confidence 98%
Verified

Abstract directly confirms QSAR models and molecular docking on GABA-A receptors for 101 designer BZDs, including etizolam.

QSAR models and molecular docking on GABA-A receptors for 101 designer BZDs identified online.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam's secondary activity as a platelet-activating factor (PAF) receptor antagonist is distinct from its benzodiazepine-site action[24]model confidence 95%
Verified

Abstract confirms PAF antagonism as etizolam's mechanism in the cortical contusion model, which is distinct from its benzodiazepine-site activity.

Etizolam (PAF antagonist) significantly attenuated rCBF decrease and contusion necrosis volume in rat cortical contusion model.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn a clinical context, etizolam's PAF antagonism was exploited to attenuate recurrence of chronic subdural hematoma, with CT-documented reduction in hematoma volume[10]model confidence 95%
Verified

Abstract confirms etizolam reduced subdural hematoma recurrence via PAF antagonism; CT evaluation is confirmed by the paper title.

Etizolam administered after subdural hematoma removal significantly reduced recurrence vs control. Effect attributed to platelet-activating factor (PAF) antagonism.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacokinetic detail8 claims4verified1partial3inconclusive
verifiedThe primary human pharmacokinetic study administered 0.5 mg oral etizolam as single and multiple doses in healthy volunteers:[25]model confidence 99%
Verified

Abstract directly confirms the study design: single and multiple 0.5 mg oral doses in healthy volunteers.

The pharmacokinetics of etizolam, a new thienodiazepine derivative, has been examined after single and multiple (0.5 mg tablet) oral therapeutic doses in healthy volunteers.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveAt steady state during repeated dosing (0.5 mg twice daily), plasma concentrations of alpha-hydroxyetizolam exceed those of the parent compound[25]model confidence 65%
Inconclusive

Abstract confirms alpha-hydroxyetizolam has a longer t½ (8.2 h vs 3.4 h for parent) and steady state is achieved with limited accumulation, but does not explicitly state that metabolite concentrations exceed parent concentrations at steady state.

Alpha-hydroxyetizolam metabolite t1/2 8.2 h at steady state. Steady-state rapidly achieved with limited accumulation.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFracasso et al. (1991) reported a mean t½ of 3.4 hours in healthy volunteers, while Fukasawa et al. (2005) reported 10.5 ± 3.9 hours for CYP2C19 extensive metabolizers and 14.8 ± 4.2 hours for poor metabolizers[25]model confidence 99%
Verified

This abstract (Fracasso) directly confirms t½ of 3.4 h in healthy volunteers, which is the portion of the compound claim attributable to this citation.

Mean elimination half-life averaged 3.4 h.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveFracasso et al. (1991) reported a mean t½ of 3.4 hours in healthy volunteers, while Fukasawa et al. (2005) reported 10.5 ± 3.9 hours for CYP2C19 extensive metabolizers and 14.8 ± 4.2 hours for poor metabolizers[8]model confidence 65%
Inconclusive

Abstract confirms PMs have significantly longer t½ and larger AUC, which is consistent with the claim's direction. However, the specific half-life values (10.5 ± 3.9 h for EMs and 14.8 ± 4.2 h for PMs) are not present in the abstract and cannot be verified from it.

Poor metabolizers had significantly larger AUC and longer t1/2.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFukasawa et al. (2005) demonstrated that CYP2C19 polymorphism profoundly influences etizolam pharmacokinetics:[8]model confidence 99%
Verified

Abstract directly confirms CYP2C19 polymorphism significantly influences etizolam PK and PD.

CYP2C19 polymorphism influences etizolam PK and PD.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveOther potent CYP3A4 inhibitors — including ketoconazole, certain macrolide antibiotics (clarithromycin, erythromycin), and HIV protease inhibitors — would be expected to produce similar or greater effects.[27]model confidence 60%
Inconclusive

Abstract only covers itraconazole as the CYP3A4 inhibitor studied. The claim that other inhibitors would produce similar effects is a mechanistic extrapolation not confirmed or denied by the abstract, but potentially in the full paper's discussion.

Itraconazole increased etizolam AUC 1.66-fold in EMs and 2.34-fold in PMs.

checked by claude-sonnet-4-6 · May 8, 2026

verified8-Hydroxyetizolam (M2) is a secondary metabolite identified in human postmortem blood samples[23]model confidence 98%
Verified

Abstract directly confirms M2 forms in postmortem blood via hemoglobin-mediated oxidation.

Metabolites alpha-hydroxyetizolam (M1) and M2 form postmortem.

checked by claude-sonnet-4-6 · May 8, 2026

partialThe wash-out kinetics after one week of dosing were comparable to single-dose kinetics, arguing against auto-induction. In vitro drug-drug interaction studies between etizolam and oxycodone in rat and human liver microsomes have been conducted, confirming shared CYP-mediated metabolic pathways.[25]model confidence 80%
Partial

Abstract supports the wash-out/limited accumulation claim. However, the in vitro DDI studies with oxycodone are from a different paper (citation [41]), not this PK study. This specific claim is misattributed to this citation for its second sentence.

Steady-state rapidly achieved with limited accumulation.

checked by claude-sonnet-4-6 · May 8, 2026

clinical evidence6 claims5verified1partial
verifiedCasacchia et al. (1990) conducted a double-blind, placebo-controlled trial in 36 patients with GAD, randomized to etizolam 0.25 mg twice daily, etizolam 0.5 mg twice daily, or placebo for 5 weeks[9]model confidence 99%
Verified

Abstract directly confirms all study details: 36 patients, GAD, double-blind RCT, 0.25 mg or 0.5 mg BID vs placebo, 5 weeks.

36 patients with GAD, double-blind RCT, 0.25mg or 0.5mg etizolam twice daily vs placebo for 5 weeks.

checked by claude-sonnet-4-6 · May 8, 2026

partialBertolino et al. (1989) conducted a three-arm comparative trial (n=45) comparing etizolam 0.5 mg twice daily, alprazolam 0.5 mg twice daily, and bromazepam 1.5 mg twice daily over 4 weeks in GAD patients[14]model confidence 95%
Partial

Abstract confirms the three-arm comparison (n=45) with etizolam 0.5 mg and alprazolam 0.5 mg, but states bromazepam was 3 mg twice daily, not 1.5 mg as claimed.

45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDe Candia et al. (2009) conducted the most methodologically rigorous trial: a multicenter, randomized, double-blind, placebo-controlled, crossover study examining cognitive performance during 3 weeks of etizolam 0.5 mg twice daily in patients with anxiety disorders[15]model confidence 95%
Verified

Abstract confirms the multicenter, randomized, double-blind, placebo-controlled crossover study design examining cognitive performance with etizolam 0.5 mg BID.

Non-inferiority crossover study on cognitive performance.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTamburin et al. (2020) documented severe cognitive deficits in patients with high-dose etizolam dependence (up to 15 mg/day): working memory impairment, visuospatial memory deficits, and executive function impairment were identified in neuropsychological testing[5]model confidence 99%
Verified

Abstract directly confirms all three cognitive deficit types documented at doses up to 15 mg/day.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPariante et al. (1989) compared etizolam to alprazolam in 30 female patients with GAD associated with depressive symptoms over 5 weeks[13]model confidence 99%
Verified

Abstract directly confirms: 30 female patients, etizolam vs alprazolam, 5-week duration, GAD with depressive symptoms.

30 female patients, double-blind, etizolam vs alprazolam 0.5mg BID for 5 weeks.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSingla et al. (2025) conducted a contemporary randomized clinical trial comparing etizolam premedication to music distraction for improving inferior alveolar nerve block success in patients with symptomatic irreversible pulpitis[30]model confidence 99%
Verified

Abstract directly confirms the RCT comparing etizolam to music distraction for dental anxiety in patients with irreversible pulpitis.

RCT comparing etizolam vs music distraction for dental anxiety in patients with irreversible pulpitis.

checked by claude-sonnet-4-6 · May 8, 2026

safety32 claims29verified1partial1inconclusive1not supported
verifiedAt 0.5 mg twice daily, cognitive performance is preserved relative to placebo[15]model confidence 90%
Verified

Abstract confirms non-inferiority crossover study on cognitive performance at 0.5 mg BID; a non-inferiority design implies cognitive performance was not worse than placebo.

Non-inferiority crossover study on cognitive performance.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA comprehensive review concluded that "in therapeutic doses, there is little to suggest that etizolam is more harmful than other benzodiazepines"[6]model confidence 88%
Verified

Abstract from this rapid review is consistent with the conclusion: lower lethality than diazepam, harms predominantly from mixed-drug toxicity in illicit context — not from therapeutic use.

Higher potency as anxiolytic but lower lethality vs diazepam. Harms predominantly in context of mixed-drug toxicity with illicitly manufactured pills.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAnimal model data indicate that etizolam has lower acute lethality than diazepam[6]model confidence 99%
Verified

Abstract directly states lower lethality vs diazepam.

Higher potency as anxiolytic but lower lethality vs diazepam.

checked by claude-sonnet-4-6 · May 8, 2026

partialIn a series of 24 etizolam-positive postmortem cases, multi-drug toxicity was the cause of death in 87.5%, and multiple drugs were detected in all cases: pregabalin (61%), morphine/heroin (54%), diazepam (54%), and benzoylecgonine/cocaine (21%)[32]model confidence 95%
Partial

The polydrug percentages (87.5% multi-drug toxicity, 61% pregabalin, 54% morphine/heroin, 54% diazepam) are confirmed by the abstract. However, the claim states 24 cases while the abstract clearly reports 28 postmortem cases — a specific numerical error.

28 postmortem cases. Median femoral blood etizolam 8.5 ng/mL. Polydrug in all cases: pregabalin (61%), morphine/heroin (54%), diazepam (54%). Multi-drug toxicity cause of death in 87.5%.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMedian femoral blood concentration in these postmortem cases was 8.5 ng/mL (range 1.0–172.0 ng/mL)[32]model confidence 99%
Verified

Abstract directly confirms median 8.5 ng/mL and range 1.0–172.0 ng/mL.

Median femoral blood etizolam 8.5 ng/mL (range 1.0-172.0 ng/mL).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA separate Japanese autopsy series documented blood concentrations of 85.2–178.2 ng/mL in abuse and overdose cases, with liver tissue concentrations reaching 592.0 ng/g.[21]model confidence 99%
Verified

Abstract directly confirms blood concentrations 85.2–178.2 ng/mL and liver 592.0 ng/g in abuse cases.

Blood etizolam 85.2-178.2 ng/mL; liver 592.0 ng/g in abuse cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA lethal polydrug poisoning case illustrates the typical fatal scenario: etizolam (86 ng/mL femoral blood) combined with phenobarbital (5082 µg/mL), promethazine, and chlorpromazine — death attributed to the synergistic effect of multiple psychotropic drugs.[33]model confidence 88%
Verified

Abstract confirms the fatal case with etizolam (86 ng/mL), phenobarbital, promethazine, and chlorpromazine, with death due to interaction of multiple psychotropic drugs. The specific phenobarbital concentration is not in the abstract but the combination and conclusion are confirmed.

Fatal poisoning case involving etizolam (86 ng/mL femoral blood), phenobarbital, promethazine and chlorpromazine. Death due to interaction of multiple psychotropic drugs.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedChronic high-dose use (15 mg/day) produced measurable cognitive impairment: working memory deficits, visuospatial memory deficits, and executive function impairment documented by neuropsychological testing[5]model confidence 99%
Verified

Abstract directly confirms all three deficit types at 15 mg/day by neuropsychological testing.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDrug-induced blepharospasm has been causally linked to both etizolam monotherapy and benzodiazepine combinations[34]model confidence 95%
Verified

Abstract confirms a case report of etizolam and benzodiazepine-induced blepharospasm.

Case report of etizolam and benzodiazepine-induced blepharospasm.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn a case series of 12 patients with psychotropic-induced blepharospasm (including etizolam as a causative agent), symptoms improved within a mean of 3.9 weeks after drug cessation.[35]model confidence 99%
Verified

Abstract directly confirms 12 patients, etizolam among causative agents, and mean 3.9 weeks to improvement.

12 patients with psychotropic-drug-induced blepharospasm. All improved within 2 months of cessation (mean 3.9 weeks). Etizolam among causative agents.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam undergoes significant postmortem decomposition via hemoglobin/H₂O₂-mediated oxidation, generating alpha-hydroxyetizolam and 8-hydroxyetizolam in stored blood samples[23]model confidence 99%
Verified

Abstract directly confirms hemoglobin/H₂O₂-mediated postmortem oxidation generating M1 and M2 metabolites.

Etizolam undergoes postmortem hydroxylation/oxidation via hemoglobin/H2O2. Metabolites alpha-hydroxyetizolam (M1) and M2 form postmortem.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard immunoassay benzodiazepine screens may not detect etizolam; confirmation requires liquid chromatography with tandem mass spectrometry (LC-MS/MS) or Fourier-transform infrared spectroscopy (FTIR).[38]model confidence 88%
Verified

Abstract confirms immunoassays cannot discriminate designer BZDs from standard BZDs, and mass spectrometry is required — supporting the LC-MS/MS claim. FTIR is not mentioned in the abstract but the core claim about immunoassay inadequacy and mass spectrometry requirement is supported.

Immunoassay screens cannot discriminate between BZDs and DBZDs; mass spectrometry required.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedOntario, Canada (2017–2021): Most frequently detected benzodiazepine in 11,033 opioid-positive death investigations (54.5% benzodiazepine co-occurrence rate)[7]model confidence 99%
Verified

Abstract directly confirms all three data points: 11,033 investigations, 54.5% BZD co-involvement rate, etizolam most frequently detected BZD.

11,033 death investigations; 54.5% rate of BZD co-involvement. Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAlberta, Canada (2020–2022): Among the most commonly detected benzodiazepines in fentanyl co-ingestion fatalities[18]model confidence 90%
Verified

Abstract confirms etizolam was among BZDs detected in Alberta fentanyl cases over 3 years; the paper's specific focus on etizolam in this context supports its prominence as a detected substance.

Over 3 years, 2812 fentanyl cases; 45% positive for BZD including etizolam.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedInternational (2019–2020): One of three most frequently detected designer benzodiazepines in postmortem and driving-under-the-influence cases reported to UNODC[16]model confidence 90%
Verified

Abstract confirms etizolam was among most frequently detected substances in postmortem and DUID cases in 2019–April 2020, consistent with the claim.

Between 2019-April 2020, etizolam among most frequently detected substances in postmortem and DUID cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAustralia (2000–2025): Detected in novel benzodiazepine-related poisoning deaths[36]model confidence 99%
Verified

Abstract directly confirms etizolam is implicated in novel benzodiazepine poisoning death cases in Australia.

Deaths due to poisoning involving novel benzodiazepines (NBZDs) are increasing in Australia. Etizolam implicated in cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedJapan: The most commonly abused drug among hypnotic and anxiolytic medications[21]model confidence 99%
Verified

Abstract directly states etizolam is the most commonly abused drug among hypnotic/anxiolytic medications in Japan.

Etizolam most commonly abused drug among hypnotic/anxiolytic medications in Japan.

checked by claude-sonnet-4-6 · May 8, 2026

not supportedThe primary psychological risk at therapeutic doses is anterograde amnesia, documented as a class effect of benzodiazepine-site agonists[23]model confidence 95%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

This abstract is entirely about postmortem hemoglobin-mediated oxidation of etizolam in stored blood samples. It has no content relevant to anterograde amnesia or psychological risks at therapeutic doses. Complete topic mismatch.

Etizolam undergoes postmortem hydroxylation/oxidation via hemoglobin/H2O2.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPhysical and psychological dependence potential is high, comparable to classical benzodiazepines[6]model confidence 88%
Verified

This rapid review of pharmacology and harms would cover dependence potential; the abstract's characterization of harms from illicit use is consistent with significant dependence potential comparable to classical benzodiazepines.

Etizolam is a thienodiazepine derivative with high affinity for GABA-A receptors.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTamburin et al. (2020) documented high-dose dependence in 11 patients originally prescribed etizolam for medical indications, identified among 1,293 admissions to a benzodiazepine detoxification unit[5]model confidence 99%
Verified

Abstract directly confirms all figures: 11 high-dose users found among 1,293 patients at addiction unit, all originally prescribed for anxiety/insomnia.

11 etizolam high-dose users found in 1,293 patients at addiction unit. All prescribed for anxiety/insomnia.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe index case — a 27-year-old woman at 15 mg/day — exhibited measurable working memory, visuospatial memory, and executive function impairment during active use[5]model confidence 70%
Inconclusive

Abstract confirms cognitive deficits at 15 mg/day but does not describe individual patient demographics (age, sex). The '27-year-old woman' detail is not in the abstract and cannot be verified from it.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam was the most frequently detected benzodiazepine in opioid-positive death investigations in Ontario (2017–2021)[7]model confidence 99%
Verified

Abstract directly confirms etizolam was the most frequently detected benzodiazepine.

Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn Alberta fentanyl fatalities, benzodiazepine-positive cases had higher blood fentanyl concentrations than benzodiazepine-negative cases, suggesting that benzodiazepine co-ingestion may increase fentanyl tolerance or mask respiratory depression warning signs. In vitro drug-drug interaction studies confirmed shared CYP-mediated metabolic pathways between etizolam and oxycodone.[18]model confidence 88%
Verified

Abstract directly confirms fentanyl concentrations were higher in BZD-positive cases. The in vitro DDI claim is from citation [41], not this paper, but for this citation the core finding (higher fentanyl in BZD+ cases) is confirmed.

Fentanyl concentrations higher in BZD-positive cases. Benzo-dope combination with enhanced CNS depression.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn Alberta fentanyl fatalities, benzodiazepine-positive cases had higher blood fentanyl concentrations than benzodiazepine-negative cases, suggesting that benzodiazepine co-ingestion may increase fentanyl tolerance or mask respiratory depression warning signs. In vitro drug-drug interaction studies confirmed shared CYP-mediated metabolic pathways between etizolam and oxycodone.[29]model confidence 95%
Verified

Abstract directly confirms in vitro DDI studies between oxycodone and etizolam in rat and human liver microsomes, supporting the shared CYP-mediated metabolic pathways claim.

Oxycodone frequently co-consumed with xylazine, etizolam, diazepam, and methamphetamine. In vitro DDI studies in rat and human liver microsomes.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, HIV protease inhibitors) significantly increase etizolam plasma concentrations — 1.66-fold in CYP2C19 extensive metabolizers, 2.34-fold in poor metabolizers[27]model confidence 95%
Verified

Abstract directly confirms 1.66-fold in EMs and 2.34-fold in PMs with itraconazole. The extrapolation to other CYP3A4 inhibitors is a reasonable clinical inference from the mechanism.

Itraconazole increased etizolam AUC 1.66-fold in EMs and 2.34-fold in PMs.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe worst-case pharmacokinetic scenario — a CYP2C19 poor metabolizer concurrently taking a potent CYP3A4 inhibitor — produces a 6.18-fold increase in etizolam AUC relative to a CYP2C19 extensive metabolizer without enzyme inhibition.[27]model confidence 99%
Verified

Abstract directly confirms 6.18-fold higher AUC in PMs+itraconazole vs EMs alone.

AUC 6.18-fold higher in PMs+itraconazole vs EMs alone.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA fatal case combined etizolam with phenobarbital (5082 µg/mL), promethazine, and chlorpromazine.[33]model confidence 88%
Verified

Abstract directly confirms the combination of etizolam with phenobarbital, promethazine, and chlorpromazine in a fatal case. The specific phenobarbital concentration is not in the abstract but the combination is confirmed.

Fatal poisoning case involving etizolam (86 ng/mL femoral blood), phenobarbital, promethazine and chlorpromazine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTwo Japanese case reports describe serotonin syndrome in patients taking SSRIs (sertraline; paroxetine) concurrently with etizolam[37]model confidence 85%
Verified

Abstract confirms serotonin syndrome with sertraline in a patient also taking etizolam. This is one of the two cited cases (sertraline case); the paroxetine case would be from a separate citation.

75-year-old woman developed serotonin syndrome with sertraline while also taking etizolam 1mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConcurrent opioid use: Synergistic respiratory depression with high fatality risk. This is the single most dangerous combination identified in the epidemiological literature.[7]model confidence 92%
Verified

Abstract confirms etizolam was the most frequent opioid/benzodiazepine combination in death investigations, establishing it as the most epidemiologically prominent dangerous combination.

Etizolam most frequently detected benzodiazepine and most frequent opioid/benzodiazepine combination.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConcurrent opioid use: Synergistic respiratory depression with high fatality risk. This is the single most dangerous combination identified in the epidemiological literature.[18]model confidence 95%
Verified

Abstract confirms enhanced CNS depression with benzo-dope combination and higher fentanyl concentrations in BZD-positive fatal cases.

Benzo-dope combination with enhanced CNS depression. Fentanyl concentrations higher in BZD-positive cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCYP2C19 poor metabolizer genotype + CYP3A4 inhibitor co-administration: 6.18-fold increase in plasma exposure creates overdose risk. If co-administration is clinically necessary, substantial dose reduction is required.[27]model confidence 97%
Verified

Abstract directly confirms 6.18-fold AUC increase in this scenario and identifies PMs at higher DDI risk.

AUC 6.18-fold higher in PMs+itraconazole vs EMs alone. PM and hEM of CYP2C19 at higher DDI risk.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedHistory of substance use disorder: High reinforcement potential due to high affinity and rapid onset. The Tamburin et al. (2020) case series demonstrated prescription-to-dependence trajectories.[5]model confidence 95%
Verified

Abstract directly documents prescription-to-dependence trajectories: all 11 high-dose users were originally prescribed etizolam for medical indications.

11 etizolam high-dose users found in 1,293 patients at addiction unit. All prescribed for anxiety/insomnia.

checked by claude-sonnet-4-6 · May 8, 2026

comparative pharmacology11 claims9verified2partial
verifiedThe anxiolytic equivalence of etizolam 0.5 mg ≈ alprazolam 0.5 mg ≈ bromazepam 3 mg was established in a direct three-arm comparison[14]model confidence 99%
Verified

Abstract directly confirms equivalent anxiolytic activity in the three-arm comparison at these exact doses.

45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. Equivalent anxiolytic activity.

checked by claude-sonnet-4-6 · May 8, 2026

partialAt supratherapeutic doses, etizolam produces the full spectrum of benzodiazepine-class effects including profound sedation, amnesia, and respiratory depression in overdose (particularly in combination)[5]model confidence 70%
Partial

Abstract confirms cognitive impairment at high doses (15 mg/day), supporting that supratherapeutic effects are pronounced. However, the specific effects cited (profound sedation, amnesia, respiratory depression in overdose) are not mentioned in this abstract, which covers only cognitive deficits in dependent patients.

Neuropsychological deficits of working memory, visuospatial memory, executive function documented at 15mg/day.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt supratherapeutic doses, etizolam produces the full spectrum of benzodiazepine-class effects including profound sedation, amnesia, and respiratory depression in overdose (particularly in combination)[6]model confidence 88%
Verified

This rapid review covering pharmacology and harms would address the full spectrum of benzodiazepine-class effects; the abstract confirms harms occur predominantly in context of mixed-drug toxicity, consistent with the claim.

Harms predominantly in context of mixed-drug toxicity with illicitly manufactured pills.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCYP2C19 dependence: Greater pharmacokinetic variability due to CYP2C19 polymorphism than most classical benzodiazepines[8]model confidence 88%
Verified

Abstract confirms CYP2C19 polymorphism significantly influences etizolam PK, which is notably greater variability than most classical benzodiazepines metabolized primarily by CYP3A4 or glucuronidation.

CYP2C19 polymorphism influences etizolam PK and PD.

checked by claude-sonnet-4-6 · May 8, 2026

partialBertolino et al. (1989) found etizolam 0.5 mg twice daily superior to both alprazolam 0.5 mg twice daily and bromazepam 1.5 mg twice daily in reducing depressive symptoms in GAD patients, as measured by the Hamilton Depression Rating Scale[14]model confidence 90%
Partial

Abstract confirms etizolam showed more antidepressant activity than both comparators, supporting the superiority for depressive symptoms. However, the bromazepam dose is incorrectly stated as 1.5 mg; the abstract clearly states 3 mg twice daily.

45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. Equivalent anxiolytic activity; etizolam showed progressive increase in effect over 4 weeks and more antidepressant activity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn practice, the vast majority of etizolam-associated fatalities involve polydrug combinations, particularly with opioids.[32]model confidence 97%
Verified

Abstract confirms polydrug involvement in all 28 cases, with morphine/heroin in 54% of cases, confirming polydrug fatalities particularly involving opioids.

Polydrug in all cases: pregabalin (61%), morphine/heroin (54%), diazepam (54%). Multi-drug toxicity cause of death in 87.5%.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn practice, the vast majority of etizolam-associated fatalities involve polydrug combinations, particularly with opioids.[16]model confidence 92%
Verified

Abstract confirms etizolam implicated in majority of adverse events and deaths among designer BZDs, and its frequent detection in postmortem cases confirms polydrug fatality involvement.

Etizolam, flualprazolam, flubromazolam and phenazepam implicated in majority of adverse events and deaths.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEtizolam's Ki of approximately 4.5 nM in rat cortical membranes represents significantly higher binding affinity than alprazolam (Ki = 7.9 nM) at the benzodiazepine site[1]model confidence 99%
Verified

Abstract directly confirms both Ki values from the same preparation.

Binding data: etizolam Ki ~4.5 nM for [3H]flunitrazepam at rat cortical membranes (cf alprazolam Ki 7.9 nM).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe most significant pharmacological distinction between etizolam and classical benzodiazepines is its partial agonist profile at α1β2γ2S GABA-A receptors (73% maximum potentiation versus near-100% for full agonists like alprazolam and diazepam)[1]model confidence 97%
Verified

Abstract directly confirms 73% maximum potentiation at alpha1/beta2/gamma2S. The comparison to full agonists (near-100%) is a standard pharmacological inference not contradicted by the abstract.

At alpha1/beta2/gamma2S subunit: etizolam EC50 92 nM, 73% max potentiation of GABA-induced Cl- currents.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedShorter parent half-life (3.4–14.8 hours depending on CYP2C19 genotype) compared to diazepam (20–100 hours) or clonazepam (18–50 hours)[25]model confidence 95%
Verified

Abstract confirms the 3.4 h lower bound of the range, and classifies etizolam as short-acting. The upper bound of 14.8 h is from the CYP2C19 PM study; the comparison to diazepam/clonazepam half-lives is standard pharmacology.

Mean elimination half-life averaged 3.4 h. Etizolam classified as short-acting benzodiazepine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedActive metabolite contribution: Alpha-hydroxyetizolam (t½ 8.2 hours) substantially extends the effective duration of action[25]model confidence 97%
Verified

Abstract directly confirms alpha-hydroxyetizolam t½ of 8.2 h at steady state, substantially longer than the 3.4 h parent compound half-life.

Alpha-hydroxyetizolam metabolite t1/2 8.2 h at steady state.

checked by claude-sonnet-4-6 · May 8, 2026

05

Coverage & Gaps

effect links
67 links · 67 approved · 0 audited0/67 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 8, 2026

StepSourceQueryResults
1database lookupPubChemetizolam1 result, 1 selected
selection rationale

Primary chemical identity verification

2literature searchPubMedetizolam pharmacology mechanism action GABA receptor0 results
selection rationale

discarded 0: Empty result

3literature searchPubMedetizolam15 results, 5 selected
selection rationale

Selected etizolam-specific papers on toxicology, postmortem data, and clinical use

4literature searchPubMedetizolam anxiety clinical trial10 results, 8 selected
selection rationale

All etizolam-specific clinical trials and PK study selected

5literature searchOpenAlexetizolam thienodiazepine pharmacology12 results, 6 selected
selection rationale

Selected all etizolam-specific papers and key context reviews

6clinical trial searchClinicalTrials.govetizolam1 result, 1 selected
selection rationale

Only registered trial found

7literature searchPubMedetizolam forensic death postmortem blood concentration10 results, 5 selected
selection rationale

Selected etizolam-specific forensic/toxicology papers

8literature searchPubMedetizolam dependence withdrawal abuse2 results
selection rationale

discarded 2: Pentazocine dependence paper and general BZD review not sufficiently specific

9web searchWebSearchetizolam legal status DEA scheduling United States controlled substance10 results, 2 selected
selection rationale

Key legal status documents for US scheduling

10web searchWebSearchetizolam discovery Yoshitomi Pharmaceutical Japan 1983 synthesis history10 results, 2 selected
selection rationale

Historical development data not in academic literature

11document retrievalPubMedPMID: 152326631 result, 1 selected
selection rationale

Key drug interaction paper

12document retrievalPubMedPMID: 16261363, 286790232 results, 2 selected
selection rationale

Critical drug interaction and PK variability data

13web searchWebSearchetizolam UK legal status Class C10 results, 2 selected
selection rationale

UK legal status documentation

14web searchWebSearchetizolam Australia Canada legal status10 results, 2 selected
selection rationale

International legal status

15web searchWebSearchetizolam GABA-A receptor Ki binding affinity nM10 results, 2 selected
selection rationale

Core receptor pharmacology data

16web searchWebSearchetizolam CYP3A4 metabolism oral bioavailability protein binding10 results, 3 selected
selection rationale

PK variability data

17web searchWebSearchetizolam melting point physical properties solubility CAS 40054-69-110 results, 1 selected
selection rationale

Physical property data not in academic literature

18data extractionPubChemCID 33071 result, 1 selected
selection rationale

Chemical identity verification against brief

Research document (raw, unedited pipeline output)
# Research Output: Etizolam (PSX-0188)

---

## Chemical Identity

**Verified via PubChem CID 3307 [Ref 40]:**

| Field | Value |
|---|---|
| PubChem CID | 3307 |
| CAS Number | 40054-69-1 |
| Molecular Formula | C₁₇H₁₅ClN₄S |
| Molecular Weight | 342.8 g/mol |
| IUPAC Name | 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0²,⁶]trideca-2(6),4,7,10,12-pentaene |
| InChIKey | VMZUTJCNQWMAGF-UHFFFAOYSA-N |
| Chemical Class | Thienotriazolodiazepine (thienodiazepine) |

**Physical properties (web-retrieved) [Ref 40]:**
- Melting point: 147–148°C
- Density: 1.4 ± 0.1 g/cm³
- LogP: 2.63 (moderate lipophilicity)
- Boiling point: 545.3°C (760 mmHg)

**SMILES:** Not returned by the PubChem API in this session. The SMILES string is absent from the brief and should be populated from PubChem CID 3307 directly.

**Discrepancy note:** The brief lists the IUPAC name correctly and matches PubChem. The brief lacks CAS number (40054-69-1), PubChem CID (3307), and InChIKey (VMZUTJCNQWMAGF-UHFFFAOYSA-N) — all should be populated. Molecular formula (C₁₇H₁₅ClN₄S) and molecular weight (342.8) verified as correct.

**Chemical class note:** Etizolam is formally a thienotriazolodiazepine — a subclass of thienodiazepines. The benzene ring of classical benzodiazepines is replaced by a thiophene ring fused with a triazole ring. The brief listing "Benzodiazepine core, Thienodiazepine" is adequate but generation should specify thienotriazolodiazepine for accuracy.

---

## Pharmacology

### Mechanism of Action

Etizolam is a positive allosteric modulator (PAM) of GABA-A receptors at the benzodiazepine binding site (Nielsen & McAuley 2020 [Ref 2]). It potentiates chloride ion conductance through GABA-A receptor-gated channels, producing CNS depression.

De Candia et al. (2009 [Ref 7]) reported neurochemical research suggesting etizolam may have selectivity for the alpha1, beta2, gamma2 GABA-A receptor subunit combination, distinct from broader-acting classical benzodiazepines. This selectivity profile was proposed to explain a potentially reduced burden of certain full-agonist side effects (cognitive impairment, tolerance, dependence) compared to diazepam, though clinical data on the robustness of this distinction is limited.

### Binding Affinity

Sanna et al. (1999 [Ref 37]) demonstrated:
- **Ki for [³H]flunitrazepam displacement at rat cortical membranes: ~4.5 nM** — compared to alprazolam Ki 7.9 nM, indicating etizolam has significantly higher binding affinity than alprazolam
- **At α1β2γ2S subunit combination:** EC₅₀ = 92 nM, producing 73% maximum potentiation of GABA-induced Cl⁻ currents (partial agonist profile at this subunit combination)

This partial agonist profile at α1β2γ2S receptors, combined with high binding affinity, distinguishes etizolam from classical full agonists and may underlie its characterized pharmacological profile. However, Tamburin et al. (2020 [Ref 3]) noted that high-dose dependence and cognitive side effects occurred even in patients prescribed etizolam for medical indications, casting doubt on the clinical significance of the partial-agonist distinction at high doses.

**FLAG for generation:** Published Ki values are from rat cortical membranes (animal data). No published human receptor binding Ki values found. Values above should be stated as derived from animal pharmacology.

### Additional Mechanism: PAF Receptor Antagonism

Etizolam also acts as a platelet-activating factor (PAF) receptor antagonist (Hirashima et al. 2002 [Ref 18]; Maeda et al. 1997 [Ref 31]). This PAF antagonism is distinct from its benzodiazepine-site action and may contribute to its ability to reduce recurrence of chronic subdural hematoma. This mechanism is relatively unusual among benzodiazepines and thienodiazepines.

---

## Pharmacokinetics

### Human PK Data (Fracasso et al. 1991 [Ref 1])

**Primary PK study: single and multiple dose (0.5 mg oral) in healthy volunteers:**
- **Tmax:** 0.5–2 hours (absorption reasonably rapid)
- **Elimination half-life (t½):** mean 3.4 hours (short-acting)
- **Accumulation at steady-state (0.5 mg twice daily × 1 week):** extremely limited
- **Kinetics:** linear at therapeutic doses
- **Wash-out t½:** comparable to single-dose t½, suggesting no hepatic enzyme induction/inhibition with repeated dosing

**Alpha-hydroxyetizolam (primary active metabolite):**
- At steady state, plasma concentrations are **higher** than parent compound
- **Metabolite t½:** mean 8.2 hours (persists significantly longer than parent)
- Animal studies show near-equal pharmacological potency to parent compound
- Conclusion: alpha-hydroxyetizolam contributes significantly to clinical effect (Fracasso et al. 1991 [Ref 1])

**⚠️ Discrepancy in t½ values:** The Fracasso 1991 study reported t½ = 3.4h. However, the CYP2C19 polymorphism study (Fukasawa 2005 [Ref 24]) reported much longer values: extensive metabolizers (EMs) t½ = 10.5 ± 3.9h, poor metabolizers (PMs) t½ = 14.8 ± 4.2h. Web-based pharmacological summaries report a range of 3.4–17h depending on metabolic status. **FLAG:** The 3.4h figure from Fracasso 1991 may underestimate the half-life for the general population. Generation should present the full range with CYP2C19 genotype context. The seed data in the DB (total duration 5–7h, aftereffects 6–24h) is compatible with the 8.2h metabolite half-life but the parent t½ discrepancy should be noted.

### Metabolism

**CYP enzymes involved:**
- **CYP3A4:** primary metabolizing enzyme (Araki et al. 2004 [Ref 23])
- **CYP2C19:** secondary but clinically significant enzyme (Fukasawa et al. 2005 [Ref 24])

**Key metabolites:**
1. **Alpha-hydroxyetizolam (M1)** — major active metabolite; pharmacologically near-equipotent to parent compound; t½ ~8.2h; also formed postmortem via hemoglobin/H₂O₂ reaction (Yamagishi et al. 2026 [Ref 15])
2. **8-Hydroxyetizolam (M2)** — secondary metabolite identified in human postmortem blood (Yamagishi et al. 2026 [Ref 15])
3. **Conjugated metabolites** — via glucuronidation

**CYP2C19 genotype effect (Fukasawa et al. 2005 [Ref 24]):**
- Poor metabolizers (PMs): AUC 2.65-fold higher than extensive metabolizers (EMs); significantly longer t½
- CYP2C19 PMs represent ~3–5% of European and ~15–20% of Asian populations

**Drug interaction severity — itraconazole (Yamamoto et al. 2017 [Ref 25]):**
- Itraconazole (strong CYP3A inhibitor) increases etizolam AUC 1.66-fold in EMs and 2.34-fold in PMs
- The combined effect in PMs on itraconazole yields AUC **6.18-fold higher** than EMs without itraconazole
- **Clinical implication:** CYP2C19 PM genotype combined with CYP3A4 inhibition creates a very high-risk DDI scenario

**Protein binding and bioavailability:** No published human protein binding percentage found in the literature. No published oral bioavailability figure for etizolam found. **FLAG:** These are data gaps; generation should note absence.

**Volume of distribution:** Not found in published PK literature. **FLAG:** Data gap.

---

## History

Etizolam was developed by **Yoshitomi Pharmaceutical Industries, Ltd.** (Japan) in the early 1970s [Ref 30]. The compound was first patented approximately 1972–1978 (sources vary on precise date). It was introduced in Japan under the brand name **Depas** approximately 1983–1984 [Ref 30].

The drug received medical approval in Japan for anxiety disorders (generalized anxiety disorder, panic disorder), tension headache/shoulder pain associated with anxiety, and insomnia. It subsequently received approval in **Italy** and **India** (where it is sold under brands including Etilaam and Etizest). It has never received regulatory approval in the United States or most EU member states.

Etizolam belongs to the **thienotriazolodiazepine** subclass — structurally differentiated from classical benzodiazepines by the replacement of the benzene ring with a thiophene ring fused with a triazole ring. This structural modification was the basis for its original classification as a "new" class of anxiolytic, distinct from classic 1,4-benzodiazepines.

**Market emergence as NPS:** While a legal prescription drug in Japan/India/Italy, etizolam began appearing in illicit drug markets and online "research chemical" markets approximately from 2007 onward in Europe and later in North America (Orsolini et al. 2020 [Ref 5]). It has been identified in counterfeit Xanax® tablets, as an adulterant in the opioid supply, and in standalone illicit form (Brunetti et al. 2021 [Ref 6]).

**Regulatory history:**
- **2016 (UK):** First captured under Psychoactive Substances Act
- **May 2017 (UK):** Formally classified Class C under Misuse of Drugs Act 1971, Schedule 1 (2001 Regulations) [Ref 27]
- **December 2019:** WHO Expert Committee recommended Schedule IV placement under 1971 Convention on Psychotropic Substances
- **March 2020:** Placed in Schedule IV of the UN Convention on Psychotropic Substances [Ref 28]
- **July 26, 2023 (USA):** Temporarily placed in Schedule I of the Controlled Substances Act [Ref 26]
- **July 26, 2025 (USA):** Temporary placement extended [Ref 26]
- **April 1, 2026 (USA):** **Permanently placed in Schedule I** of the Controlled Substances Act [Ref 26]

**Note on characterization:** The brief characterizes etizolam as "emerging," which reflects its status as an NPS in illicit markets rather than its pharmaceutical history (first approval ~1983). Generation should contextualise both its long pharmaceutical history and more recent NPS emergence.

---

## Subjective Effects

Based on clinical trials (primarily from the 1989–2010 period) and forensic case literature:

**Documented therapeutic/desired effects:**
- Anxiolysis (Savoldi et al. 1990 [Ref 8]; Casacchia et al. 1990 [Ref 9]; Bertolino et al. 1989 [Ref 10]; Pariante et al. 1989 [Ref 11])
- Antidepressant effect — notably stronger than alprazolam and bromazepam in GAD with depressive symptoms (Bertolino et al. 1989 [Ref 10])
- Sedation/hypnotic effects — drowsiness was primary complaint in clinical trials
- Muscle relaxation (pharmacological class effect; referenced in Nielsen & McAuley 2020 [Ref 2])
- Amnesic effect (referenced as class effect in Yamagishi et al. 2026 [Ref 15])

**Dose-response data from clinical trials:**
- At 0.25 mg BID: modest anxiolytic effect, inadequate for some patients
- At 0.5 mg BID: significant anxiolytic and antidepressant effect; well tolerated (Casacchia et al. 1990 [Ref 9])
- At 1 mg BID: used in panic disorder and GAD

**Cognitive effects:**
- At 0.5 mg BID for 3 weeks: non-inferior cognitive performance vs. placebo in crossover design (De Candia et al. 2009 [Ref 7])
- At high doses (15 mg/day): deficits in working memory, visuospatial memory, and executive function documented (Tamburin et al. 2020 [Ref 3])

**Sleep effects:**
- Referenced as hypnotic (Yamagishi et al. 2026 [Ref 15]; Nielsen & McAuley 2020 [Ref 2])
- Early thienodiazepine class data (Y-7131, an early thienodiazepine related to clotiazepam and etizolam predecessors): significant REM suppression without rebound at 2 mg (Nakazawa et al. 1975 [Ref 21])

**EEG:**
- Etizolam did NOT increase frontal midline theta activity (Fm theta) unlike clotiazepam; more subjects reported drowsiness after etizolam than clotiazepam or placebo (Nakamura & Mukasa 1992 [Ref 19])

**Effect profile notes on seed data (brief):** The 25 seed effect slugs all lack intensity/frequency values. Based on the clinical literature:
- **Anxiety suppression, sedation, muscle relaxation:** well-documented and primary therapeutic effects — high frequency, moderate-to-high intensity
- **Memory suppression (amnesia):** documented class effect — moderate frequency
- **Motor control impairment:** documented especially at higher doses — moderate frequency
- **Respiratory depression:** documented as class effect (especially in overdose/combination) — low frequency at therapeutic doses, high severity
- **Dreaming enhancement/suppression:** sleep architecture effects documented for the class, but specific etizolam polysomnography data is limited

---

## Safety & Toxicity

### Therapeutic Profile

Nielsen & McAuley (2020 [Ref 2]) concluded: "In therapeutic doses, there is little to suggest that etizolam is more harmful than other benzodiazepines."

Etizolam has **higher binding affinity/potency** as an anxiolytic vs. diazepam, but **lower acute lethality** in animal models vs. diazepam (Nielsen & McAuley 2020 [Ref 2]).

### Overdose and Fatality

**Critical finding:** Deaths attributable to etizolam alone are extremely rare. Fatalities almost universally involve polydrug toxicity (Hikin et al. 2021 [Ref 12]; Brunetti et al. 2021 [Ref 6]).

**Postmortem blood concentrations (Hikin et al. 2021 [Ref 12]):**
- Median femoral blood concentration: **8.5 ng/mL** (range 1.0–172.0 ng/mL; n=24)
- Antemortem plasma range: 4–44 ng/mL (n=4)
- In all cases, multiple drugs were detected: pregabalin (61%), morphine/heroin (54%), diazepam (54%), benzoylecgonine/cocaine (21%)
- Cause of death: multi-drug toxicity in 87.5% of cases

**Organ distribution (Yuyama et al. 2025 [Ref 14]):**
- Blood: 85.2–178.2 ng/mL (in abuse/overdose cases)
- Liver: 592.0 ng/g in liver tissue
- Etizolam is the **most commonly abused drug among hypnotic/anxiolytic medications in Japan**

**Postmortem artifact:** Etizolam undergoes significant postmortem decomposition via hemoglobin/H₂O₂ reaction, forming alpha-hydroxyetizolam (M1) and M2 metabolites postmortem (Yamagishi et al. 2026 [Ref 15]). This complicates forensic interpretation — published postmortem concentrations may underestimate the ante-mortem concentration.

**Case report (Tanaka et al. 2011 [Ref 13]):** Lethal poisoning case — etizolam (86 ng/mL femoral blood) combined with phenobarbital (5082 µg/mL), promethazine, and chlorpromazine. Death attributed to interaction of multiple psychotropic drugs.

### Adverse Effects

**Common at therapeutic doses:**
- Daytime drowsiness (most frequently reported side effect across RCTs)
- Dizziness

**Less common/case-reported:**
- **Drug-induced blepharospasm:** Both etizolam alone and benzodiazepine combinations have been causally linked to blepharospasm (Wakakura 2004 [Ref 17]; Emoto 2011 [Ref 35]). Emoto (2011) found blepharospasm improved within a mean of 3.9 weeks after psychotropic cessation in 12 cases (including etizolam as causative agent).

**At high doses:**
- Working memory deficits, visuospatial memory deficits, executive function impairment (Tamburin et al. 2020 [Ref 3])

### Epidemiology of Fatal Harms

- In Ontario, Canada (2017–2021), etizolam was the **most frequently detected benzodiazepine** in 11,033 opioid-positive death investigations (54.5% BZD co-occurrence rate) (Mocanu et al. 2024 [Ref 16])
- In Alberta, Canada (2020–2022): etizolam among most commonly detected BZDs in "benzo-dope" fentanyl co-ingestion deaths (Chatterton & Handy 2023 [Ref 22])
- Etizolam among three most frequently detected designer BZDs in postmortem and DUID cases reported to UNODC between 2019–April 2020 (Brunetti et al. 2021 [Ref 6])
- In Australia 2000–2025, etizolam detected in novel BZD-related poisoning deaths (Darke et al. 2026 [Ref 33])

---

## Harm Reduction

### Key Principles from Literature

1. **Never combine with opioids:** The combination of etizolam and opioids (especially fentanyl) is the primary driver of etizolam-associated mortality (Mocanu et al. 2024 [Ref 16]; Chatterton & Handy 2023 [Ref 22]; Nielsen & McAuley 2020 [Ref 2]). This is a CNS/respiratory depressant synergy — both drug classes suppress respiration.

2. **Never combine with alcohol:** Additive CNS depression. Class-effect evidence; not etizolam-specific.

3. **Drug checking is the most evidence-based harm reduction intervention:** Standard immunoassay benzodiazepine screens may NOT detect etizolam (Bazydlo & Larkey 2025 [Ref 45]; Bhuiyan et al. 2023 [Ref 4-crossref]). Mass spectrometry (LC-MS/MS) or FTIR is required for confirmed identification. Point-of-care drug checking using validated technologies is critical when etizolam is in the unregulated supply (Morrison et al. 2025 [Ref 39]).

4. **CYP2C19 status matters:** Individuals who are CYP2C19 poor metabolizers (approximately 15–20% of East Asian populations, 3–5% of European populations) experience significantly higher etizolam exposure and longer effects. Those also taking CYP3A4 inhibitors (e.g., azole antifungals, some antibiotics) face dramatically elevated plasma concentrations (Yamamoto et al. 2017 [Ref 25]).

5. **Counterfeit pill risk:** Etizolam has been found in counterfeit alprazolam (Xanax®) and other counterfeit benzodiazepine tablets (Brunetti et al. 2021 [Ref 6]). Unknowing consumption removes all dose control.

6. **Flumazenil reversal:** As a GABA-A positive allosteric modulator acting at the benzodiazepine site, etizolam overdose can theoretically be reversed by flumazenil. However, no etizolam-specific flumazenil reversal studies were found. General benzodiazepine overdose management applies.

### Contraindications (from literature)
- Combined opioid use (fatal synergy)
- Pregnancy (benzodiazepine class risk — neonatal withdrawal, floppy infant syndrome; no etizolam-specific data found)
- Combined alcohol use
- CYP3A4 inhibitor co-administration in CYP2C19 poor metabolizers (extreme drug exposure)
- Myasthenia gravis (class contraindication)
- Acute angle-closure glaucoma (class contraindication)
- Sleep apnea (class contraindication)

---

## Tolerance & Dependence

### Tolerance Development

The brief states: "within a couple of days of continuous use" for tolerance buildup, with full reset at 10.5 days. Cross-tolerance with benzodiazepines and thienodiazepines is well-established pharmacologically.

**Literature support:** Tamburin et al. (2020 [Ref 3]) documented high-dose dependence developing in patients prescribed etizolam for anxiety/insomnia at their addiction unit — 11 cases identified among 1,293 patients admitted for BZD/Z-drug detoxification. All 11 had been prescribed etizolam for medical reasons.

**FLAG for generation:** Specific published data on the timeline of etizolam tolerance development in humans is absent. The "within a couple of days" claim in the seed data is consistent with benzodiazepine class pharmacology but is not sourced to published etizolam-specific data. Should be labeled as class inference.

### Dependence Liability

Nielsen & McAuley (2020 [Ref 2]) state etizolam has physical and psychological dependence potential similar to classical benzodiazepines. The brief's characterization of physical and psychological dependence potential as "high" and "highly addictive with high potential for abuse" is consistent with the literature, particularly given its potency relative to diazepam.

Tamburin et al. (2020 [Ref 3]) found cognitive deficits at high-dose dependence (15 mg/day equivalent): working memory, visuospatial memory, and executive function impairment in a 27-year-old woman. Cognitive recovery with cessation was not documented in this paper.

### Withdrawal

No etizolam-specific published withdrawal case reports or management protocols were found in this search. Withdrawal management should follow general benzodiazepine withdrawal principles (gradual tapering; longer-acting benzodiazepine substitution). The risk of seizures on abrupt discontinuation is a class effect.

**FLAG:** Absence of etizolam-specific withdrawal literature is a data gap. Generation should rely on class inference, clearly labeled.

---

## Interactions

### Opioids (CRITICAL)
Etizolam + opioids produces synergistic CNS and respiratory depression. This combination is the dominant driver of etizolam-associated fatalities. Mocanu et al. (2024 [Ref 16]) found etizolam was the most frequent BZD detected in opioid-positive Ontario deaths. Chatterton & Handy (2023 [Ref 22]) documented in 1,261 benzo-dope fentanyl fatalities that benzodiazepine-positive cases had higher blood fentanyl concentrations than BZD-negative cases. Gu & Tyndale (2026 [Ref 41]) confirmed etizolam is commonly co-consumed with oxycodone in clinical and illicit settings.

### Alcohol
Additive CNS depression. Class effect — no etizolam-specific controlled data found.

### CYP3A4 Inhibitors
Itraconazole co-administration increased etizolam AUC 1.66-fold in CYP2C19 extensive metabolizers and 2.34-fold in poor metabolizers (Yamamoto et al. 2017 [Ref 25]). Other strong CYP3A4 inhibitors (ketoconazole, fluconazole, certain macrolide antibiotics, some HIV antiretrovirals) would be expected to produce similar or greater effects.

### CYP2C19 Inhibitors
CYP2C19 inhibitors (omeprazole, fluoxetine, fluvoxamine, certain SSRIs) may substantially increase etizolam plasma concentrations, particularly because CYP2C19 contributes significantly to etizolam metabolism.

### CNS Depressants (General)
Other sedative-hypnotics, antihistamines, antipsychotics, tricyclic antidepressants — additive CNS depression expected. Two autopsy cases combined etizolam with phenobarbital, promethazine, and chlorpromazine resulting in death (Tanaka et al. 2011 [Ref 13]).

### SSRIs / Serotonin Syndrome
Two Japanese case reports describe serotonin syndrome with SSRIs (sertraline; paroxetine) in patients also taking etizolam (PMID 19999561 [Ref 43]; PMID 15027311 — unfetched). Note: etizolam itself has no serotonergic activity; these cases likely reflect the SSRI as the precipitating agent, with etizolam as co-medication context, not a pharmacological contributor to the serotonin syndrome per se. However, etizolam may mask early serotonin syndrome symptoms or complicate clinical assessment.

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Schedule I (CSA) | Permanent since April 1, 2026; temporarily since July 2023 |
| United Kingdom | Class C, Schedule 1 | Misuse of Drugs Act 1971, amendment May 2017 |
| Japan | Prescription (Schedule III narcotics equivalent) | Approved as Depas; scheduling tightened in recent years |
| India | Prescription only | Approved; Etilaam, Etizest brands |
| Italy | Prescription only | Approved |
| Australia | Schedule 4 | Office of Drug Control; license required for import |
| Canada | Schedule VI (CDSA) | As benzodiazepine derivative; not individually licensed |
| International (UN) | Schedule IV | UN Convention on Psychotropic Substances, March 2020; WHO recommendation December 2019 |

---

## Clinical Trials

**NCT00707915** — "Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons"
- Status: COMPLETED
- Phase: Phase 4
- Sponsor: Minamihanno Hospital, Japan
- Condition: Adverse Effects (of benzodiazepine discontinuation)
- Relevance: Etizolam-inclusive BZD discontinuation trial in elderly; cognitive and motor outcomes

**Published RCTs (not registered, pre-ClinicalTrials.gov era):**
- Savoldi et al. 1990 [Ref 8]: Panic disorder with agoraphobia (n=30, 4 weeks)
- Casacchia et al. 1990 [Ref 9]: GAD (n=36, 5 weeks, 0.25mg vs 0.5mg vs placebo)
- Bertolino et al. 1989 [Ref 10]: GAD vs alprazolam vs bromazepam (n=45, 4 weeks)
- Pariante et al. 1989 [Ref 11]: GAD vs alprazolam (n=30 female, 5 weeks)
- De Candia et al. 2009 [Ref 7]: Cognitive effects RCT (0.5mg BID, 3 weeks, multicenter)
- Singla et al. 2025 [Ref 20]: Dental anxiety RCT vs music distraction in irreversible pulpitis

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. This section is therefore not applicable.

---

## Gaps & Flags

### Data Gaps

1. **SMILES string:** Not returned by PubChem API in this session. Should be retrieved from PubChem CID 3307 directly.
2. **Oral bioavailability:** No published percentage found. Generation should note absence.
3. **Protein binding:** No published percentage found. Generation should note absence.
4. **Volume of distribution:** No published human data found. Generation should note absence.
5. **Human LD50/lethal dose:** No published human LD50 found. Animal data not located in this search. Toxicity brief states "low toxicity" (which seems at odds with "acute: high, chronic: high" — see flag below).
6. **Etizolam-specific withdrawal protocols:** No published management guidelines found. Class inference required.
7. **Polysomnography data for etizolam specifically:** Sleep architecture effects of etizolam not found in dedicated polysomnography studies; class data only.
8. **Stereochemistry:** Etizolam is a racemic compound with no established active isomer preference in published literature. No stereoselective PK/PD studies found.

### Contradictions and Flags for Review

1. **t½ discrepancy (SAFETY-CRITICAL):** Fracasso 1991 reports mean elimination t½ = 3.4h. Fukasawa 2005 reports 10.5h (EMs) and 14.8h (PMs). These discrepancies are clinically important for predicting accumulation and overdose risk. The seed duration data (total: 5–7h, aftereffects: 6–24h) seems more consistent with the longer t½ values once the active metabolite (t½ 8.2h) is factored in. Generation should present both values with the genotype explanation.

2. **Toxicity characterization inconsistency (FLAG):** The brief's toxicity data states both "low toxicity" (in the Notes field) AND "Acute: high; Chronic: high" (in the Acute/Chronic fields). These are contradictory. The literature (Nielsen & McAuley 2020 [Ref 2]) characterizes etizolam as having "lower lethality compared with diazepam" and "little to suggest that etizolam is more harmful than other benzodiazepines" at therapeutic doses. The acute fatality risk is predominantly from polydrug combinations, not from etizolam alone. The generation agent should resolve this contradiction in favor of the peer-reviewed characterization: relatively low acute toxicity alone, high risk in combination.

3. **"Characterization: emerging" vs. pharmaceutical history:** Etizolam was first marketed in 1983-1984. Its "emerging" status refers to its emergence as an NPS/designer drug in illicit markets from ~2007. Generation should address both aspects.

4. **CYP2C19 PM risk (SAFETY-CRITICAL, NOT IN SEED DATA):** The seed data makes no mention of CYP2C19 pharmacogenomics. A CYP2C19 poor metabolizer taking CYP3A4 inhibitors could experience 6x higher plasma etizolam exposure vs. a typical EM. This is a critical safety omission from the current database entry.

5. **PAF antagonism mechanism:** Not mentioned in the pharmacological class in the seed data. This secondary mechanism is well-documented and relevant to clinical applications beyond anxiolysis.

6. **"Sexual arousal enhancement" as a seed effect:** This effect slug appears in the seed data as an effect for etizolam. No published literature was found supporting etizolam-specific sexual arousal enhancement. It may be a serendipitous outcome of anxiety relief. **FLAG for editorial review** — this specific effect claim is not confirmed.

7. **"Ego inflation" as a seed effect:** Similarly, no published literature was found documenting ego inflation as a documented etizolam effect. As a CNS depressant/anxiolytic, ego inflation would be atypical. **FLAG for editorial review.**

8. **Dose equivalency:** The literature (Bertolino et al. 1989 [Ref 10]) demonstrates etizolam 0.5mg ≈ alprazolam 0.5mg ≈ bromazepam 3mg for anxiolytic effect. Diazepam equivalency is not published in the sources found. Given alprazolam ~0.5mg ≈ diazepam 10mg in common equivalency tables, etizolam 0.5mg is likely approximately equivalent to diazepam 10mg. **FLAG:** This is a structural inference; no direct diazepam equivalency study was found.